Andreas Hochhaus

Q: What Schools Are Affiliated With Andreas Hochhaus

Andreas Hochhaus is affiliated with the following schools: Medical University of Vienna, Ludwig Maximilian University of Munich, University of Basel, University of Turin, University of Jena, Catholic University of Korea, Imperial College London, Kobe University, Royal Postgraduate Medical School, University of Adelaide, University of São Paulo, University of Bologna, University of Southampton, Heidelberg University

Andreas Hochhaus's AcademicInfluence.com Rankings

Andreas Hochhaus

Philosophy

#3729

World Rank

#5969

Historical Rank

Logic

#1363

World Rank

#2094

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Andreas Hochhaus Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Andreas Hochhaus's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. (2003) (3476)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. (2006) (3337)
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. (2002) (2065)
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. (2013) (1736)
Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. (2013) (1374)
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. (2006) (1300)
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. (2003) (1294)
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. (2006) (1286)
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. (2009) (1255)
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. (2010) (1224)
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. (2002) (1196)
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. (2006) (1186)
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders (2010) (1114)
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. (2002) (1068)
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy (2002) (940)
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. (2013) (878)
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. (2005) (871)
Long‐Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia (2017) (754)
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. (2007) (747)
International randomized study of interferon Vs STI571 (IRIS) 8-year follow up: Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (2009) (659)
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia (2020) (623)
Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. (2016) (615)
Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia (2007) (614)
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. (2007) (608)
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial (2016) (595)
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. (2010) (593)
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. (2002) (574)
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). (2012) (561)
Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects (2003) (550)
Chronic myeloid leukaemia (2007) (547)
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia (2010) (516)
BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. (2011) (501)
Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. (2008) (482)
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. (2011) (475)
Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). (2010) (463)
Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. (1994) (454)
Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up (2012) (432)
Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. (2012) (430)
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia (2009) (422)
Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. (2007) (420)
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML) (2012) (401)
Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. (2008) (391)
Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). (2014) (381)
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. (2018) (378)
Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. (2007) (376)
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms (2022) (373)
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. (2011) (364)
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib (2008) (363)
Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. (2007) (359)
Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells. (2007) (356)
Standardized definitions of molecular response in chronic myeloid leukemia (2012) (344)
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia (2016) (341)
Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications (2006) (339)
Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. (2009) (332)
Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance (2004) (323)
Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. (2001) (322)
Liposomal encapsulated anti-cancer drugs. (2005) (320)
Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia. (2011) (315)
Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. (2018) (309)
Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases (2002) (300)
Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial (2017) (300)
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms (2022) (293)
Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. (2009) (288)
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. (2008) (288)
Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR (1999) (286)
The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. (2005) (271)
Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia (2015) (270)
Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. (2014) (269)
Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. (2011) (262)
Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib (2010) (250)
Response and resistance in 300 patients with BCR‐ABL–positive leukemias treated with imatinib in a single center (2005) (248)
Lack of clinical efficacy of imatinib in metastatic melanoma (2005) (246)
Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. (2014) (239)
Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). (2007) (225)
Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. (2008) (223)
Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development (2005) (216)
Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV (2015) (213)
Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study (2017) (212)
Harmonization of molecular monitoring of CML therapy in Europe (2009) (212)
The concept of treatment-free remission in chronic myeloid leukemia (2016) (211)
Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study (2013) (211)
Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia (2006) (209)
Comprehensive mutational profiling in advanced systemic mastocytosis. (2013) (208)
Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. (2010) (208)
Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. (2007) (199)
Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction. (1996) (198)
Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. (2016) (195)
Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis (2013) (195)
Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase (2008) (194)
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants (2017) (189)
Roots of Clinical Resistance to STI-571 Cancer Therapy (2001) (188)
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells (2018) (187)
Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon α (2002) (185)
Molecular heterogeneity in complete cytogenetic responders after interferon-α therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission (2000) (178)
The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation (2020) (177)
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. (2019) (177)
Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia (2000) (172)
BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia (2011) (171)
Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. (2010) (168)
A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases (2011) (165)
Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation. (2006) (165)
p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias. (1996) (159)
The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA. (2002) (156)
Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. (2014) (156)
Chronic myeloid leukaemia. (2007) (154)
Metabolic gatekeeper function of B-lymphoid transcription factors (2016) (154)
Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma (2007) (154)
Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV. (2015) (153)
Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. (2010) (152)
Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. (2012) (148)
Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2017) (142)
Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II). (2012) (141)
A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia. (1996) (139)
Loss of p53 impedes the antileukemic response to BCR-ABL inhibition. (2006) (134)
Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial. (2009) (133)
Widespread occurrence of the JAK 2 V 617 F mutation in chronic myeloproliferative disorders (2005) (132)
Dasatinib in imatinib‐resistant or ‐intolerant chronic‐phase, chronic myeloid leukemia patients: 7‐year follow‐up of study CA180‐034 (2016) (132)
Interferon-α, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia (2003) (131)
Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-C (2003) (130)
Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1(+) leukemia. (2011) (130)
Should a platelet limit of 600 × 109/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages (1998) (128)
The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis (2013) (125)
Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis (2006) (124)
Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. (2005) (124)
The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome‐negative cells (2007) (124)
Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib (2014) (123)
Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status (2014) (121)
Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2017) (119)
Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib (2008) (119)
Centrosome aberrations in chronic myeloid leukemia correlate with stage of disease and chromosomal instability (2005) (118)
Dasatinib in imatinib‐resistant or imatinib‐intolerant chronic myeloid leukemia in blast phase after 2 years of follow‐up in a phase 3 study (2010) (118)
Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome – a phase‐II study (2008) (118)
Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. The German CML Study Group. (1998) (118)
Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation. (2009) (116)
Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial (2008) (115)
Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. (2007) (113)
Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study (2018) (113)
Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients (2006) (113)
The effect of prior exposure to imatinib on transplant-related mortality. (2006) (112)
Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories (2008) (112)
Interferon consensus sequence binding protein (ICSBP; IRF-8) antagonizes BCR/ABL and down-regulates bcl-2. (2004) (111)
Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia : an analysis from the International Randomized Study of Interferon and STI 571 ( IRIS ) * (2010) (111)
Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients. (2016) (109)
Detection and quantification of residual disease in chronic myelogenous leukemia (2000) (109)
Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique (2003) (108)
A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV (2007) (101)
Molecular monitoring of response to imatinib (Glivec®) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission (2003) (100)
Clinical resistance to imatinib: mechanisms and implications. (2004) (96)
Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study. (2005) (96)
Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis (2021) (96)
Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study (2015) (93)
Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib. (2012) (93)
Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up (2012) (92)
Expression of nuclear transcription factor interferon consensus sequence binding protein in chronic myeloid leukemia correlates with pretreatment risk features and cytogenetic response to interferon-alpha. (2001) (91)
Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase (2012) (90)
Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib. (2012) (90)
Real-time quantitative Y chromosome-specific PCR (QYCS-PCR) for monitoring hematopoietic chimerism after sex-mismatched allogeneic stem cell transplantation. (2001) (90)
An Open-Label, Phase I Study of the Polo-like Kinase-1 Inhibitor, BI 2536, in Patients with Advanced Solid Tumors (2010) (90)
Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. (2013) (90)
Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib (2014) (89)
A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer (2007) (89)
Cetuximab-Based Treatment of Metastatic Anal Cancer: Correlation of Response with KRAS Mutational Status (2009) (89)
Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure. (1999) (88)
Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate (2003) (85)
Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results (2012) (85)
Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease. (2011) (85)
PTEN opposes negative selection and enables oncogenic transformation of pre-B cells (2016) (84)
Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene. (2007) (84)
Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia (2019) (84)
Randomized comparison of interferon α and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon α and hydroxyurea (2003) (84)
The t(8;17)(p11;q23) in the 8p11 myeloproliferative syndrome fuses MYO18A to FGFR1 (2005) (83)
Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group. (2000) (83)
Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia. (2011) (82)
Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia. (2007) (82)
Four Years of Follow-Up of 1027 Patients with Late Chronic Phase (L-CP), Accelerated Phase (AP), or Blast Crisis (BC) Chronic Myeloid Leukemia (CML) Treated with Imatinib in Three Large Phase II Trials. (2004) (82)
Quantification of residual disease in Philadelphia-positive acute lymphoblastic leukemia: comparison of blood and bone marrow. (1995) (82)
Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany (2009) (81)
Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis (2010) (81)
Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase (2012) (81)
Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. (2016) (80)
Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2‐PDGFRA fusion gene (2006) (80)
Overexpression of SOCS-2 in advanced stages of chronic myeloid leukemia: possible inadequacy of a negative feedback mechanism. (2002) (80)
Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history (2010) (78)
Treatment and outcome of 2904 CML patients from the EUTOS population-based registry (2017) (78)
Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome‐positive leukemias with the T315I mutation (2017) (78)
Imatinib as a treatment option for systemic non-Langerhans cell histiocytoses. (2007) (77)
Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure–response analysis of a Phase III study (2013) (76)
Variable numbers of BCR‐ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon‐α (1995) (76)
Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3. (2011) (76)
Resistance to targeted therapy in chronic myelogenous leukemia. (2007) (75)
Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer. (2008) (74)
Gender aspects in chronic myeloid leukemia: long-term results from randomized studies (2005) (74)
JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia. (2007) (74)
A certified plasmid reference material for the standardisation of BCR–ABL1 mRNA quantification by real-time quantitative PCR (2014) (72)
In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures. (2005) (72)
A Phase 3, Open-Label, Randomized Study of Asciminib, a STAMP Inhibitor, vs Bosutinib in CML After ≥2 Prior TKIs. (2021) (72)
Capecitabine (Cape) versus 5-fluorouracil (5-FU)-based (neo)adjuvant chemoradiotherapy (CRT) for locally advanced rectal cancer (LARC): Long-term results of a randomized, phase III trial. (2011) (72)
Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase (2015) (71)
Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. (2003) (71)
Impact of BCR-ABL mutations on patients with chronic myeloid leukemia (2011) (70)
B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell Malignancies (2018) (69)
Results of comprehensive geriatric assessment effect survival in patients with malignant lymphoma (2011) (69)
Final Study Results of the Phase 3 Dasatinib Versus Imatinib in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Trial (DASISION, CA180-056) (2014) (68)
Cytogenetic and molecular mechanisms of resistance to imatinib. (2003) (68)
Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet. (2012) (67)
Induction of centrosome and chromosome aberrations by imatinib in vitro (2005) (67)
Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia. (2013) (66)
Transcription factor mutations in myelodysplastic/myeloproliferative neoplasms (2010) (66)
Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia (2011) (66)
Genomic anatomy of the specific reciprocal translocation t(15;17) in acute promyelocytic leukemia (2003) (64)
Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV (2016) (63)
Adjuvant Therapy with Edrecolomab versus Observation in Stage II Colon Cancer: A Multicenter Randomized Phase III Study* (2005) (63)
Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. (2011) (63)
Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia (2018) (63)
Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia (2011) (62)
Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis (2007) (61)
Chronic myelogenous leukemia: molecular and cellular aspects (1998) (61)
Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic‐phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors (2013) (61)
Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML (2015) (61)
Improvement of molecular monitoring of residual disease in leukemias by bedside RNA stabilization (2002) (60)
ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia (2008) (60)
Hemophagocytic lymphohistiocytosis in adults: collaborative analysis of 137 cases of a nationwide German registry (2020) (60)
BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase (2015) (60)
IRIS 6-Year Follow-Up: Sustained Survival and Declining Annual Rate of Transformation in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib. (2007) (59)
A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial (2012) (58)
Chronic myeloid leukemia: clinical impact of BCR-ABL1 mutations and other lesions associated with disease progression. (2012) (58)
Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia? (2020) (58)
Chronic myeloid leukemia: a model for oncology (2005) (58)
Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms (2020) (58)
Properties of the solutions of rational matrix difference equations (2003) (57)
Epic: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML) (2014) (57)
Educational session: managing chronic myeloid leukemia as a chronic disease. (2011) (57)
MK-0457, an Aurora kinase and BCR–ABL inhibitor, is active in patients with BCR–ABL T315I leukemia (2013) (57)
Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV (2013) (57)
Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase (2013) (57)
An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCR. (2007) (57)
Phase 1 study of INNO‐406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome‐positive leukemias after imatinib resistance or intolerance (2010) (56)
Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy (2011) (55)
Subclones with the t(9;22)/BCR‐ABL1 rearrangement occur in AML and seem to cooperate with distinct genetic alterations (2011) (55)
Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia (2015) (55)
KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer. (2011) (55)
Comparative analysis of the impact of risk profile and of drug therapy on survival in CML using Sokal's index and a new score (1997) (55)
Early results from a phase I study on orally administered tris(8-quinolinolato)gallium(III) (FFC11, KP46) in patients with solid tumors--a CESAR study (Central European Society for Anticancer Drug Research--EWIV). (2005) (55)
Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation (2012) (54)
Dasatinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) In the DASISION Trial: 18-Month Follow-up (2010) (54)
The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients (2013) (53)
Long-Term Follow-up of Ponatinib Efficacy and Safety in the Phase 2 PACE Trial (2014) (53)
The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis (2013) (53)
Lack of correlation between ABL‐BCR expression and response to interferon‐α in chronic myeloid leukaemia (1996) (53)
Update On Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) On Nilotinib Therapy at 24 Months: Clinical Response, Safety, and Long-Term Outcomes. (2009) (53)
Onco-Cardiology: Consensus Paper of the German Cardiac Society, the German Society for Pediatric Cardiology and Congenital Heart Defects and the German Society for Hematology and Medical Oncology (2020) (53)
Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib. (2011) (52)
Cessation of Tyrosine Kinase Inhibitors Treatment in Chronic Myeloid Leukemia Patients with Deep Molecular Response: Results of the Euro-Ski Trial (2016) (52)
A Phase I Study of IDH305 in Patients with Advanced Malignancies Including Relapsed/Refractory AML and MDS That Harbor IDH1R132 Mutations (2016) (52)
Adhesion to fibronectin stimulates proliferation of wild-type and bcr/abl-transfected murine hematopoietic cells. (1999) (51)
Clonal aberrations in Philadelphia chromosome negative hematopoiesis in patients with chronic myeloid leukemia treated with imatinib or interferon alpha (2005) (51)
Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib. (2013) (51)
Efficacy and Safety of Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Long-Term Follow-Up (f/u) of ENESTnd (2014) (50)
The use of complementary and alternative medicine by patients in routine care and the risk of interactions (2018) (49)
ENESTnd Update: Continued Superiority of Nilotinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) (2010) (49)
Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies (2014) (49)
ENESTnd Update: Nilotinib (NIL) Vs Imatinib (IM) In Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) and The Impact Of Early Molecular Response (EMR) and Sokal Risk At Diagnosis On Long-Term Outcomes (2013) (49)
Isochromosome breakpoints on 17p in medulloblastoma are flanked by different classes of DNA sequence repeats (2006) (49)
Interim Analysis of a Pan European Stop Tyrosine Kinase Inhibitor Trial in Chronic Myeloid Leukemia : The EURO-SKI study (2014) (49)
Ponatinib may overcome resistance of FLT3‐ITD harbouring additional point mutations, notably the previously refractory F691I mutation (2012) (48)
BCR–ABL Transcript Dynamics Support the Hypothesis That Leukemic Stem Cells Are Reduced during Imatinib Treatment (2011) (48)
Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase (2010) (48)
Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML (2017) (48)
Cyclin A1 is predominantly expressed in hematological malignancies with myeloid differentiation (1998) (47)
Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scale. (2013) (47)
Targeting HSP90 dimerization via the C terminus is effective in imatinib-resistant CML and lacks the heat shock response. (2018) (47)
Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia (2014) (47)
On a class of rational matrix differential equations arising in stochastic control (2004) (47)
Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study (2015) (46)
Ponatinib Dose-Ranging Study in Chronic-Phase Chronic Myeloid Leukemia: A Randomized, Open-Label Phase 2 Clinical Trial. (2021) (46)
Expression of interferon regulatory factor 4 in chronic myeloid leukemia: correlation with response to interferon alfa therapy. (2000) (46)
Expert opinion—management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors (2020) (46)
Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale (2016) (46)
Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment (2015) (45)
Expression of interferon regulatory factor (IRF) genes and response to interferon-α in chronic myeloid leukaemia (1997) (44)
Safety and Efficacy of Subcutaneous-Administered Omacetaxine Mepesuccinate in Imatinib-Resistant Chronic Myeloid Leukemia (CML) Patients Who Harbor the Bcr- Abl T315I Mutation–Results of An Ongoing Multicenter Phase 2/3 Study. (2009) (44)
Dasatinib versus imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): DASISION 3-year follow-up. (2012) (44)
Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib (2008) (43)
Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity (2016) (43)
BCR-ABL mutations in chronic myeloid leukemia. (2011) (43)
Molecular monitoring of chronic myeloid leukemia: principles and interlaboratory standardization (2015) (42)
Dasatinib pharmacokinetics and exposure-response (E-R): Relationship to safety and efficacy in patients (pts) with chronic myeloid leukemia (CML) (2008) (42)
Current trends in the management of chronic myelogenous leukemia (2000) (42)
Enestnd 4-Year (y) Update: Continued Superiority of Nilotinib Vs Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome–Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP) (2012) (42)
ABL-BCR expression does not correlate with deletions on the derivative chromosome 9 or survival in chronic myeloid leukemia. (2001) (42)
Identification of a MYO18A‐PDGFRB fusion gene in an eosinophilia‐associated atypical myeloproliferative neoplasm with a t(5;17)(q33‐34;q11.2) (2009) (41)
Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome—positive acute lymphoblastic leukemia (2013) (41)
Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients (2012) (41)
A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib (2009) (41)
Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value (2009) (41)
Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure. (2006) (41)
Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily (2014) (41)
Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib (2013) (40)
Nilotinib in Chronic Myeloid Leukemia Patients in Accelerated Phase (CML-AP) with Imatinib Resistance or Intolerance: 2-Year Follow-up Results of a Phase 2 Study (2008) (40)
Early Response (Molecular and Cytogenetic) and Long-Term Outcomes in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Analysis of DASISION 3-Year Data (2012) (40)
Outcome of Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Based On Early Molecular Response and Factors Associated with Early Response: 4-Year Follow-up Data From Enestnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials Newly Diagnosed Patients) (2012) (40)
Chronic myelogenous leukemia (CML): resistance to tyrosine kinase inhibitors. (2006) (39)
Nilotinib Demonstrates Superior Efficacy Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: Results From the International Randomized Phase III ENESTnd Trial (2009) (39)
Quality assurance in RT-PCR-based BCR/ABL diagnostics – results of an interlaboratory test and a standardization approach (2000) (39)
Six-year (yr) follow-up of patients (pts) with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia (CML-CP) receiving dasatinib. (2011) (39)
Polymorphisms of Toll-like receptors (TLR2 and TLR4) are associated with the risk of infectious complications in acute myeloid leukemia (2014) (39)
Dose-dependent severe cutaneous reactions to imatinib (2003) (38)
Capecitabine-associated hand–foot–skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer (2012) (37)
Nilotinib Is Highly Active and Safe in Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Patients with Imatinib-Resistance or Intolerance. (2007) (37)
Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 24-month follow-up. (2010) (37)
Four-Year (Yr) Follow-Up Of Patients (Pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) Receiving Dasatinib Or Imatinib: Efficacy Based On Early Response (2013) (36)
Centrosome aberrations after nilotinib and imatinib treatment in vitro are associated with mitotic spindle defects and genetic instability (2007) (36)
Dasatinib 50 mg or 70 mg BID compared to 100 mg or 140 mg QD in patients with CML in chronic phase (CP) who are resistant or intolerant to imatinib: One-year results of CA180034 (2007) (36)
CEBPA Mutations in 4708 Patients with Acute Myeloid Leukemia - Differential Impact of bZIP and TAD Mutations on Outcome. (2021) (36)
Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor–Sensitive and -Resistant Chronic Myeloid Leukemia (2016) (35)
Influenza virus infections in patients with malignancies –– characteristics and outcome of the season 2014/15. A survey conducted by the Infectious Diseases Working Party (AGIHO) of the German Society of Haematology and Medical Oncology (DGHO) (2016) (35)
Molecular monitoring of residual disease in chronic myelogenous leukemia patients after therapy. (1998) (35)
Impact of Dose Intensity of Ponatinib on Selected Adverse Events: Multivariate Analyses from a Pooled Population of Clinical Trial Patients (2014) (35)
e8a2 BCR–ABL: more frequent than other atypical BCR–ABL variants? (2005) (35)
Erratum: Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia(Leukemia (2009) 23 (1054-1061) DOI: 10.1038/leu.2009.38) (2010) (35)
Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML (2018) (35)
Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase (2017) (34)
Efficacy and Safety of Nilotinib In Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (Pts) with Type 2 Diabetes In the ENESTnd Trial. (2010) (34)
Randomized Comparison of Interferon-a With Busulfan and Hydroxyurea in Chronic Myelogenous Leukemia (2002) (34)
Activating CBL mutations are associated with a distinct MDS/MPN phenotype (2012) (34)
Combined adjuvant radiochemotherapy with IMRT/XELOX improves outcome with low renal toxicity in gastric cancer. (2009) (33)
No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib (2017) (33)
Dasatanib (D) in patients (pts) with chronic myelogenous leukemia (CML) in lymphoid blast crisis (LB-CML) or Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ALL) who are imatinib (IM)-resistant (IM-R) or intolerant (IM-I): The CA180015 'START-L' study. (2006) (33)
Diagnosis and management of chronic myeloid leukemia (2007) (33)
Comparison of Real-Time quantitative PCR and digital droplet PCR for BCR-ABL1 Monitoring in Patients with Chronic Myeloid Leukemia. (2019) (33)
Safety and Efficacy of Subcutaneous-Administered Omacetaxine Mepesuccinate in Chronic Myeloid Leukemia (CML) Patients Who Are Resistant or Intolerant to Two or More Tyrosine Kinase Inhibitors – Results of A Multicenter Phase 2/3 Study. (2009) (33)
The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia (2020) (33)
AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has significant activity in imatinib-resistant bcr-abl positive chronic myeloid leukemia (CML) (2005) (32)
Centrosome aberrations and G1 phase arrest after in vitro and in vivo treatment with the SRC/ABL inhibitor dasatinib (2008) (32)
Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia (2011) (32)
Two potential mechanisms of oxaliplatin-induced haemolytic anaemia in a single patient (2004) (32)
Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study (2020) (32)
Molecular and chromosomal mechanisms of resistance in CML patients after STI571 (Glivec) therapy (2001) (32)
International standardisation of quantitative real-time RT-PCR for BCR-ABL. (2008) (32)
Randomized Comparison of Imatinib 800 Mg Vs. Imatinib 400 Mg +/- IFN in Newly Diagnosed BCR/ABL Positive Chronic Phase CML: Analysis of Molecular Remission at 12 Months; The German CML-Study IV. (2009) (32)
ENESTnd 5-year (y) update: Long-term outcomes of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib (NIL) versus imatinib (IM). (2014) (32)
Paraneoplastic inflammation in myelodysplastic syndrome or bone marrow failure: case series with focus on 5‐azacytidine and literature review (2014) (32)
Frequent ASXL1 mutations in children and young adults with chronic myeloid leukemia (2018) (32)
In Vivo Emergence of UL56 C325Y Cytomegalovirus Resistance to Letermovir in a Patient with Acute Myeloid Leukemia after Hematopoietic Cell Transplantation (2019) (32)
Polymorphisms of Dectin-1 and TLR2 Predispose to Invasive Fungal Disease in Patients with Acute Myeloid Leukemia (2016) (31)
A Phase I Study of INNO-406 in Patients with Advanced Philadelphia (Ph+) Chromosome-Positive Leukemias Who Are Resistant or Intolerant to Imatinib and Second Generation Tyrosine Kinase Inhibitors. (2007) (31)
Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1‐JAK2, BCR‐JAK2 and ETV6‐ABL1 fusion genes (2020) (31)
Patients with malignant hematological disorders treated on a palliative care unit: prognostic impact of clinical factors (2014) (31)
High BCR–ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib (2017) (31)
Dasatinib and Imatinib-Induced Reductions in BCR-ABL Transcript Levels Below 10% At 3 Months Are Associated with Improved Responses in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Analysis of Molecular Response Kinetics in the DASISION Trial (2011) (31)
Continuing Reduction in Level of Residual Disease after 4 Years in Patients with CML in Chronic Phase Responding to First-Line Imatinib (IM) in the IRIS Study. (2005) (30)
Rarity of dominant-negative mutations of the G-CSF receptor in patients with blast crisis of chronic myeloid leukemia or de novo acute leukemia (1997) (30)
IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisis (2011) (30)
Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study. (2009) (29)
Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients (2015) (29)
Normalization of Previously Shortened Telomere Length under Treatment with Imatinib Argues against a Preexisting Telomere Length Deficit in Normal Hematopoietic Stem Cells from Patients with Chronic Myeloid Leukemia (2003) (29)
Standardization of Preanalytical Factors for Minimal Residual Disease Analysis in Chronic Myelogenous Leukemia (2004) (29)
A somatic EZH2 mutation in childhood acute myeloid leukemia (2012) (29)
Responses and Disease Progression in CML-CP Patients Treated with Nilotinib after Imatinib Failure Appear To Be Affected by the BCR-ABL Mutation Status and Types. (2007) (29)
Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial (2021) (29)
A Phase II Study of Dasatinib in Patients with Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis or Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Who Are Resistant or Intolerant to Imatinib: The ‘START-L’ CA180015 Study. (2005) (29)
Is a Recurrent Abnormality in Chronic and Acute Leukemia that Fuses PCM 1 to JAK 2 (2005) (28)
Complete molecular remission of chronic eosinophilic leukemia complicated by CNS disease after targeted therapy with imatinib (2004) (28)
Imatinib and beyond—the new CML study IV (2004) (28)
The risk of infections in multiple myeloma before and after the advent of novel agents: a 12-year survey (2019) (28)
Resistenz auf tumorspezifische Therapie mit Imatinib durch klonale Selektion mutierter Zellen (2002) (27)
A Phase II Study of Nilotinib A Novel Tyrosine Kinase Inhibitor Administered to Imatinib-Resistant or Intolerant Patients with Chronic Myelogenous Leukemia (CML) in Accelerated Phase (AP). (2006) (27)
Nilotinib ( formerly AMN 107 ) , a highly selective BCR-ABL tyrosine kinase inhibitor , is active in patients with imatinib-resistant or-intolerant accelerated-phase chronic myelogenous leukemia (2008) (27)
Superparamagnetic iron oxide nanoparticles exert different cytotoxic effects on cells grown in monolayer cell culture versus as multicellular spheroids (2015) (27)
Efficacy of Dasatinib in Patients with Chronic-Phase Chronic Myelogenous Leukemia with Resistance or Intolerance to Imatinib: 2-Year Follow-Up Data from START-C (CA180-013). (2007) (27)
Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV (2018) (27)
Human MAIT cells are rapidly activated by Aspergillus spp. in an APC‐dependent manner (2018) (27)
The molecular anatomy of the FIP1L1-PDGFRA fusion gene (2009) (27)
Asciminib, a First-in-Class STAMP Inhibitor, Provides Durable Molecular Response in Patients (pts) with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: Primary Efficacy and Safety Results from a Phase 1 Trial (2020) (27)
Response-related predictors of survival in CML (2015) (27)
Monitoring of minimal residual disease in chronic myeloid leukemia. (2004) (27)
Panniculitis in a patient with chronic myelogenous leukaemia treated with imatinib (2003) (27)
Minimal residual disease in chronic myeloid leukaemia patients. (2002) (27)
Efficacy of Dasatinib in Patients with Chronic Phase Philadelphia Chromosome-Positive CML Resistant or Intolerant to Imatinib: First Results of the CA180013 ‘START-C’ Phase II Study. (2005) (26)
Isoform localization of Dectin‐1 regulates the signaling quality of anti‐fungal immunity (2017) (26)
A phase I study of INNO-406 in patients with advanced Philadelphia chromosome-positive (Ph+) leukemias who are resistant or intolerant to imatinib and may have also failed second-generation tyrosine kinase inhibitors. (2008) (26)
EZH2 mutations and promoter hypermethylation in childhood acute lymphoblastic leukemia (2016) (26)
Dasatinib Dose-Optimization in Chronic Phase Chronic Myeloid Leukemia (CML-CP): Two-Year Data from CA180-034 Show Equivalent Long-Term Efficacy and Improved Safety with 100 Mg Once Daily Dose (2008) (25)
High-risk additional chromosomal abnormalities at low blast counts herald death by CML (2020) (25)
Dasatinib in patients with chronic phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to imatinib: Results of the CA180013 'START-C' Study. (2006) (25)
Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib (2017) (25)
Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance (2013) (25)
A polymorphism associated with STAT3 expression and response of chronic myeloid leukemia to interferon α (2010) (25)
Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis (2019) (25)
Nilotinib in patients with imatinib-resistant or -intolerant chronic myelogenous leukemia in chronic phase (CML-CP): Updated phase II results (2008) (25)
Expanded Phase 1 Study of ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Reveals Significant and Durable Responses in Patients with CML-Chronic Phase with Failure of Prior TKI Therapy (2016) (25)
Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine (2021) (25)
Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST). (2004) (24)
Incidence of Hyperglycemia by 3 Years in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib (NIL) or Imatinib (IM) in ENESTnd (2012) (24)
STOPPING TYROSINE KINASE INHIBITORS IN A VERY LARGE COHORT OF EUROPEAN CHRONIC MYELOID LEUKEMIA PATIENTS: RESULTS OF THE EURO-SKI TRIAL (2016) (24)
Reduced risk for chronic myelogenous leukemia in individuals with the cytochrome P-450 gene polymorphism CYP1A1*2A (2001) (24)
BCR‐ABL‐positive progenitors in chronic myeloid leukaemia patients in complete cytogenetic remission after treatment with interferon‐α (1998) (24)
Molecular response of CML patients treated with interferon-alpha monitored by quantitative Southern blot analysis. German chronic myeloid leukaemia (CML) Study Group. (1997) (24)
Adjuvant IMRT/XELOX radiochemotherapy improves long-term overall- and disease-free survival in advanced gastric cancer (2013) (24)
Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia. (2017) (24)
ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Exhibits Safety and Promising Single- Agent Activity in a Phase I Study of Patients with CML with Failure of Prior TKI Therapy (2015) (24)
Clinical impact of dose modification and dose intensity on response to ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias. (2014) (24)
Efficacy of Dasatinib (SPRYCEL®) in Patients (pts) with Chronic Phase Chronic Myelogenous Leukemia (CP-CML) Resistant to or Intolerant of Imatinib: Updated Results of the CA180013 ‘START-C’ Phase II Study. (2006) (24)
AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has Significant Activity in Imatinib-Resistant Chronic Myeloid Leukemia (CML) or Philadelphia-Chromosome Positive Acute Lymphoid Leukemia (Ph + ALL). (2005) (24)
Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia (2012) (24)
Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase (2014) (23)
The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia (2013) (23)
Minimal cross-intolerance between nilotinib and imatinib in patients with imatinib-intolerant chronic myelogenous leukemia (CML) in chronic phase (CP) or accelerated phase (AP) (2008) (23)
Clinical decision making in chronic myeloid leukemia based on polymerase chain reaction analysis of minimal residual disease. (1999) (23)
The results of imatinib therapy for patients with primary eosinophilic disorders (2006) (23)
Mutational analysis of the p15 and p16 genes in acute leukaemias (1996) (23)
Interim Results from Fight-203, a Phase 2, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Pemigatinib (INCB054828) in Patients with Myeloid/Lymphoid Neoplasms with Rearrangement of Fibroblast Growth Factor Receptor 1 (FGFR1) (2018) (23)
Atypical mRNA fusions in PML‐RARA positive, RARA‐PML negative acute promyelocytic leukemia (2010) (23)
Frequent polymorphism in BCR exon b2 identified in BCR-ABL positive and negative individuals using fluorescent hybridization probes (2000) (23)
Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis (2015) (22)
Dasatinib Efficacy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Pre-Existing BCR-ABL Mutations (2008) (22)
The c-kit (CD117) sequence variation M541L, but not N564K, is frequent in the general population, and is not associated with CML in Caucasians (2006) (22)
MDR1 expression predicts outcome of Ph+ chronic phase CML patients on second-line nilotinib therapy after imatinib failure (2014) (22)
Do persons with chronic myeloid leukaemia have normal or near normal survival? (2019) (22)
Treatment-free remission (TFR) following nilotinib (NIL) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): ENESTfreedom, ENESTop, ENESTgoal, and ENESTpath. (2014) (22)
Cause and management of therapy resistance. (2009) (22)
Telomere length in peripheral blood granulocytes reflects response to treatment with imatinib in patients with chronic myeloid leukemia. (2003) (22)
Presentation, Treatment, and Analysis of Prognostic Factors of Terminally ill Patients with Gastrointestinal Tumors (2009) (22)
Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV (2014) (21)
Current treatment concepts of CML. (2011) (21)
Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment (2017) (21)
Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure (2007) (21)
A CLASS OF NONLINEAR DIFFERENTIAL EQUATIONS ON THE SPACE OF SYMMETRIC MATRICES (2004) (21)
Dasatinib 140 Mg Once Daily (QD) Demonstrates Equivalent Efficacy and Improved Safety Compared with 70 Mg Twice Daily (BID) in Patients with Chronic Myeloid Leukemia in Blast Phase (CML-BP): 2-Year Data from CA180-035 (2008) (21)
Comparison of bone marrow high mitotic index metaphase fluorescence in situ hybridization to peripheral blood and bone marrow real time quantitative polymerase chain reaction on the International Scale for detecting residual disease in chronic myeloid leukemia (2008) (21)
Dasatinib or imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Two-year follow-up from DASISION. (2011) (21)
Impact of FLT3-ITD diversity on response to induction chemotherapy in patients with acute myeloid leukemia (2017) (21)
Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSCT) (2002) (21)
Bosutinib (BOS) Versus Imatinib for Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukemia (CML): Final 5-Year Results from the Bfore Trial (2020) (21)
High-Dose 5-Fluorouracil / Folinic Acid in Combination with Three-Weekly Mitomycin C in the Treatment of Advanced Gastric Cancer. A Phase II Study (2002) (21)
Lack of correlation between ABL-BCR expression and response to interferon-alpha in chronic myeloid leukaemia. (1996) (20)
The European LeukemiaNet: achievements and perspectives (2011) (20)
Nilotinib Versus Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTnd 36-Month (mo) Follow-up (2011) (20)
Randomized study of the combination of hydroxyurea and interferon alpha versus hydroxyurea monotherapy during the chronic phase of chronic myelogenous leukemia (CML Study II). The German CML Study Group. (1996) (20)
Physical and psychosocial aspects of adolescent and young adults after allogeneic hematopoietic stem-cell transplantation: results from a prospective multicenter trial (2017) (20)
Adjuvant therapy sparing in rectal cancer achieving complete response after chemoradiation. (2014) (20)
Limited Efficacy of Ponatinib in Myeloproliferative Neoplasms Associated with FGFR1 Fusion Genes (2015) (20)
ABL-kinase domain point mutation as a cause of imatinib (STI571) resistance in CML patient who progress to myeloid blast crisis. (2003) (20)
Molecular characterization of EZH2 mutant patients with myelodysplastic/myeloproliferative neoplasms (2017) (20)
How long will chronic myeloid leukemia patients treated with imatinib mesylate live? (2005) (19)
Genotyping of 25 leukemia-associated genes in a single work flow by next-generation sequencing technology with low amounts of input template DNA. (2013) (19)
The Interlaboratory Robustness Of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses Of Hematological Malignancies Performed In 8,867 Cases By An International Network Involving 27 Laboratories (2012) (19)
Telomere shortening correlates with leukemic stem cell burden at diagnosis of chronic myeloid leukemia. (2018) (19)
Dasatinib-Associated Major Molecular Responses Are Rapidly Achieved in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Following Resistance, Suboptimal Response, or Intolerance on Imatinib. (2008) (19)
Expression of interferon-alpha (IFN-alpha) receptor 2c at diagnosis is associated with cytogenetic response in IFN-alpha-treated chronic myeloid leukemia. (2001) (19)
Capecitabine (Cape) versus 5-fluorouracil (5-FU)-based (neo-)adjuvant chemoradiotherapy (CRT) for locally advanced rectal cancer (LARC): Safety results of a randomized, phase III trial. (2009) (19)
Prevalence and dynamics of clonal hematopoiesis caused by leukemia-associated mutations in elderly individuals without hematologic disorders (2020) (19)
Nilotinib Is Associated with Minimal Cross Intolerance to Imatinib in Patients with Imatinib-Intolerant Philadelphia-Positive (Ph+) Chronic Myelogenous Leukemia (CML) in Either Chronic Phase (CP) or Accelerated Phase (AP). (2007) (19)
Treatment-free remission in FIP1L1-PDGFRA-positive myeloid/lymphoid neoplasms with eosinophilia after imatinib discontinuation. (2020) (19)
Bosutinib is safe and active in patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML) with resistance or intolerance to imatinib and other tyrosine kinase inhibitors (2008) (19)
EZH2 in Myeloid Malignancies (2020) (19)
[Resistance to tumor specific therapy with imatinib by clonal selection of mutated cells]. (2002) (19)
Long-term follow-up of the AML97 study for patients aged 60 years and above with acute myeloid leukaemia: a study of the East German Haematology and Oncology Study Group (OSHO) (2015) (19)
LASP1 is a novel BCR-ABL substrate and a phosphorylation-dependent binding partner of CRKL in chronic myeloid leukemia (2014) (19)
Suitability of Viability Assays for Testing Biological Effects of Coated Superparamagnetic Nanoparticles (2013) (18)
SIRT7: an influence factor in healthy aging and the development of age-dependent myeloid stem-cell disorders (2020) (18)
The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AML (2019) (18)
Nilotinib versus imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 3-year (yr) follow-up (f/u). (2012) (18)
Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin (2019) (18)
Clinical Management of Posterior Reversible Encephalopathy Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation: A Case Series and Review of the Literature (2015) (18)
Reconstitution and functional analyses of neutrophils and distinct subsets of monocytes after allogeneic stem cell transplantation (2011) (18)
Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV (2018) (18)
Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation (2015) (18)
Expression of the p210BCR-ABL oncoprotein drives centrosomal hypertrophy and clonal evolution in human U937 cells (2007) (18)
A phase II study of nilotinib administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in accelerated phase (AP) (2007) (18)
Novel myelofibrosis treatment strategies: potential partners for combination therapies (2014) (18)
Proliferating status of peripheral blood progenitor cells from patients with BCR/ABL-positive chronic myelogenous leukemia (2001) (18)
Successful allogeneic stem cell transplantation in second chronic-phase CML induced by the tyrosine kinase inhibitor nilotinib (AMN107) after blast crisis under imatinib (2007) (18)
Five Year Follow-Up Results of a Phase II Trial in Patients with Late Chronic Phase (L-CP) Chronic Myeloid Leukemia (CML) Treated with Imatinib Who Are Refractory/Intolerant of Interferon-α. (2005) (17)
Impact of Treatment with Frontline Nilotinib (NIL) vs Imatinib (IM) on Sustained Deep Molecular Response (MR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) (2015) (17)
Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation (2009) (17)
Leukemic Stem Cell Quantification in Newly Diagnosed Patients With Chronic Myeloid Leukemia Predicts Response to Nilotinib Therapy (2016) (17)
Time from Diagnosis to Treatment Does Not Affect Outcome in Intensively Treated Patients with Newly Diagnosed Acute Myeloid Leukemia. (2019) (17)
Management of Bcr–Abl-positive leukemias with dasatinib (2007) (17)
Cardiac Safety Profile of Imatinib and Nilotinib In Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Results From ENESTnd (2010) (17)
Nilotinib Efficacy According to Baseline BCR-ABL Mutations in Patients with Imatinib-Resistant Chronic Myeloid Leukemia in Chronic Phase (CML-CP) (2008) (17)
The German CML study, comparison of busulfan vs. hydroxyurea vs. interferon alpha and establishment of prognostic score 1. (1993) (17)
Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis (2017) (17)
A phase I repeated dose escalation study of the Polo-like kinase 1 inhibitor BI 2536 in patients with advanced solid tumours. (2006) (17)
Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study (2020) (17)
Dasatinib compared to imatinib (IM) in patients (pts) with newly diagnosed chronic-phase chronic myelogenous leukemia in chronic phase (CML-CP): Twelve-month efficacy and safety from the phase III DASISION study. (2010) (17)
Safety and Efficacy of Dasatinib (DAS) Vs. Imatinib (IM) by Baseline Comorbidity In Patients with Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of the DASISION Trial. (2010) (17)
Gefitinib in Combination with 5-Fluorouracil (5-FU)/Folinic Acid and Irinotecan in Patients with 5-FU/Oxaliplatin- Refractory Colorectal Cancer: A Phase I/II Study of the Arbeitsgemeinschaft für Internistische Onkologie (AIO) (2006) (17)
Dasatinib (SPRYCEL®) Efficacy and Safety in Patients (pts) with Chronic Myelogenous Leukemia in Lymphoid (CML-LB) or Myeloid Blast (CML-MB) Phase Who Are Imatinib-Resistant (Im-r) or -Intolerant (Im-i). (2006) (17)
Magnetic particle spectroscopy allows precise quantification of nanoparticles after passage through human brain microvascular endothelial cells (2016) (17)
Ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation: Longer-term follow up of the PACE trial. (2014) (16)
Detection of centrosome aberrations in disease‐unrelated cells from patients with tumor treated with tyrosine kinase inhibitors (2010) (16)
Molecular Response to First Line Imatinib Therapy Is Predictive for Long Term Event Free Survival in Patients with Chronic Phase Chronic Myelogenous Leukemia – An Interim Analysis of the Randomized German CML Study IV (2008) (16)
Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 12-Month Follow-up of the PACE Trial (2012) (16)
Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib (2015) (16)
Biomarker candidates for the detection of an infectious etiology of febrile neutropenia (2016) (16)
Efficacy of dasatinib in chronic phase chronic myelogenous leukemia patients after imatinib failure according to baseline BCR- ABL mutations (2007) (16)
A Phase II Study of Nilotinib, a Novel Inhibitor of c-Kit, PDGFR, and Bcr-Abl, Administered to Patients with Systemic Mastocytosis. (2006) (16)
Impact of dose reductions on 5-year efficacy in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) from DASISION. (2017) (16)
Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon alpha. (2003) (16)
Dasatinib (SPRYCEL®) 50mg or 70mg BID Versus 100mg or 140mg QD in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Resistant or Intolerant to Imatinib: Results of the CA180-034 Study. (2006) (15)
Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (15)
Information needs and usage of complementary and alternative medicine in members of a German self-help group for gastrointestinal stroma tumours, sarcoma, and renal cancer. (2018) (15)
Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205 (2013) (15)
EZH2 mutations and impact on clinical outcome: an analysis in 1,604 patients with newly diagnosed acute myeloid leukemia (2020) (15)
Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon α (2003) (15)
Interim analysis (IA) of OPTIC: A dose-ranging study of three ponatinib (PON) starting doses. (2020) (15)
"Duration of Deep Molecular Response" Has Most Impact on the Success of Cessation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia - Results from the EURO-SKI Trial (2017) (15)
Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs (2020) (15)
Imatinib restores expression of CD62L in BCR‐ABL‐positive cells (2003) (15)
Imatinib mesylate, a new kid on the block for the treatment of anti‐neutrophil cytoplasmic autoantibodies‐associated vasculitis? (2008) (14)
Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission (2020) (14)
Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial (2022) (14)
First-Line management of CML: a state of the art review. (2008) (14)
Prediction of Molecular Response of Chronic Phase CML Patients by the EUTOS Score: Results of the Randomized CML-Study IV, (2011) (14)
Dasatinib dose-optimization study in chronic phase chronic myeloid leukemia (CML-CP): Three-year follow-up with dasatinib 100 mg once daily and landmark analysis of cytogenetic response and progression-free survival (PFS). (2016) (14)
EPIC: A phase III trial of ponatinib (PON) versus imatinib (IM) in patients (pts) with newly diagnosed CP-CML. (2014) (14)
Impact of NOD2 polymorphisms on infectious complications following chemotherapy in patients with acute myeloid leukaemia (2013) (14)
Activity of AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, in imatinib-resistant bcr-abl positive lymphoid malignancies (2005) (14)
Enhanced Bcr-Abl-specific antileukemic activity of arsenic trioxide through glutathione-depletion in imatinib-resistant cells (2007) (14)
Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Treated with Ponatinib in the PACE Trial (2012) (14)
Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (GemOx): A randomized phase II trial in advanced pancreatic cancer (2005) (14)
Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia (2019) (14)
Capecitabine in combination with mitomycin C in patients with gastrointestinal cancer: results of an extended multicentre phase-I trial (2004) (14)
Development, Function, and Clinical Significance of Plasmacytoid Dendritic Cells in Chronic Myeloid Leukemia. (2018) (14)
Detection of drug-resistant clones in chronic myelogenous leukemia patients during dasatinib and nilotinib treatment. (2010) (14)
BCL 6-mediated repression of p 53 is critical for leukemia stem cell survival in chronic myeloid leukemia (2011) (14)
Ponatinib In Patients (pts) With Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Resistant Or Intolerant To Dasatinib Or Nilotinib, Or With The T315I BCR-ABL Mutation: 2-Year Follow-Up Of The PACE Trial (2013) (13)
Safety and Efficacy of Subcutaneous (SC) Omacetaxine Mepesuccinate in Imatinib(IM)-Resistant Chronic Myeloid Leukemia (CML) Patients (pts) with the T315I Mutation – Results of An Ongoing Multicenter Phase II Study. (2008) (13)
Anti-oxidant vitamin E prevents accumulation of imatinib-resistant BCR-ABL1 kinase mutations in CML-CP xenografts in NSG mice (2013) (13)
Clinical, social, and psycho-oncological needs of adolescents and young adults (AYA) versus older patients following hematopoietic stem cell transplantation (2020) (13)
Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia (2013) (13)
Isolated central nervous system relapse of chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation (2012) (13)
Interactions in cancer treatment considering cancer therapy, concomitant medications, food, herbal medicine and other supplements (2021) (13)
Phase II study of Sorafenib (BAY 43-9006) in hormone-refractory patients with prostate cancer: A study of the Central European Society for Anticancer Drug Research-EWIV (CESAR). (2006) (13)
Open-Label Phase II Evaluation of Imatinib in Primary Inoperable or Incompletely Resected and Recurrent Glioblastoma (2019) (13)
Molecular and Cytogenetic Response After 3 Months of Imatinib Treatment Is Predictive for the Risk of Disease Progression and Death in Newly Diagnosed Chronic Myeloid Leukemia Patients – a Follow-up Analysis of the German CML Study IV (2011) (13)
Molecular pathogenesis of tyrosine kinase resistance in chronic myeloid leukemia (2010) (13)
A Phase-Ib/II Study of Ruxolitinib Plus Pomalidomide in Myelofibrosis (2015) (13)
Treatment of a Patient with Advanced Esophageal Cancer with a Combination of Mitomycin C and Capecitabine: Activation of the Thymidine Phosphorylase as Active Principle? (2003) (13)
Lack of association of platelet-derived growth factor (PDGF) receptor autoantibodies and severity of chronic graft-versus-host disease (GvHD) (2013) (13)
Updated Results from the German Mpnsg-0212 Combination Trial: Ruxolitinib Plus Pomalidomide in Myelofibrosis with Anemia (2019) (13)
Paul Ehrlichs „magic bullets“ (2013) (12)
Bosutinib (BOS) versus imatinib (IM) for newly diagnosed chronic myeloid leukemia (CML): Initial results from the BFORE trial. (2017) (12)
Ponatinib Efficacy and Safety in Patients with the T315I Mutation: Long-Term Follow-up of Phase 1 and Phase 2 (PACE) Trials (2014) (12)
Advances in the treatment of haematological malignancies: optimal sequence of CML treatment. (2007) (12)
Bosutinib vs imatinib for newly diagnosed chronic myeloid leukemia in the BFORE trial: 24-month follow-up. (2018) (12)
Corrections to "Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up". (2018) (12)
Efficacy and Safety Results from Ascembl, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, Vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase after ≥2 Prior Tyrosine Kinase Inhibitors: Update after 48 Weeks (2021) (12)
Randomized Comparison of Imatinib 400 Mg Vs. Imatinib + IFN Vs. Imatinib + AraC Vs. Imatinib after IFN Vs. Imatinib 800 Mg: Optimized Treatment and Survival. Designed First Interim Analysis of the German CML Study IV (2008) (12)
Continuous Complete Hematological and Cytogenetic Remission with Molecular Minimal Residual Disease 9 Years after Discontinuation of Interferon-α in a Patient with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (2006) (12)
Protein Tyrosine Kinases. From Inhibitors to Useful Drugs (2006) (12)
Molecular response of CML patients treated with interferon‐α monitored by quantitative Southern blot analysis (1997) (12)
Complementary and alternative medicine (CAM) supplements in cancer outpatients: analyses of usage and of interaction risks with cancer treatment (2021) (12)
Nilotinib in Imatinib-Resistant or -Intolerant Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 48-Month Follow-up Results of a Phase 2 Study, (2011) (12)
Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation (2020) (12)
Efficacy of Different Regimens of Adjuvant Radiochemotherapy for Treatment of Glioblastoma (2007) (12)
PTPRG and PTPRC modulate nilotinib response in chronic myeloid leukemia cells (2018) (12)
Pattern and Evolution of BCR-ABL Kinase Domain Mutations in Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Developing Resistance to Imatinib. (2005) (12)
Management of Acute Myeloid Leukemia: Current Treatment Options and Future Perspectives (2021) (11)
Nilotinib Shows Safety and Efficacy in Older Patients (≥ 65 years) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase Comparable with That in Younger Patients with Chronic Myeloid Leukemia in Chronic Phase: Results From ENESTnd, (2011) (11)
Frequency of CTLA-4 Receptor Ligand (CD86, B7.2) -Positive Plasmacytoid Dendritic Cells Predicts Risk of Disease Recurrence after Tyrosine-Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Results from a Prospective Substudy of the Euroski Trial (2015) (11)
Efficacy and Safety of Ponatinib (PON) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Who Failed One or More Second-Generation (2G) Tyrosine Kinase Inhibitors (TKIs): Analyses Based on PACE and Optic (2020) (11)
Cytogenetic response to prior treatment with interferon-α is predictive for survival after allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia (2006) (11)
Molecular Response After 3 Months of 1st Line Imatinib Therapy Is Predictive for Treatment Failure and Disease Progression In Patients with Chronic Phase Chronic Myeloid Leukemia - a Follow-up Analysis of the German CML Study IV (2010) (11)
Nilotinib Lowers the Incidence of BCR-ABL Mutations and Improves the Molecular Response Kinetics Compared with Imatinib in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia (CML). (2010) (11)
Secondary resistance to sorafenib in two patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations (2011) (11)
Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia. (2021) (11)
Compassionate Use of Sorafenib in Relapsed and Refractory Flt3-ITD Positive Acute Myeloid Leukemia. (2009) (11)
Efficacy and Safety Of Ponatinib Following Failure Of Dasatinib In Patients (pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML) In The PACE Trial (2013) (11)
Primary Results of the Phase 4 BYOND Study of Bosutinib for Pretreated Chronic Phase (CP) Chronic Myeloid Leukemia (CML) (2019) (11)
Efficacy and Safety of Ponatinib in CP-CML Patients By Number of Prior Tyrosine Kinase Inhibitors: 4-Year Follow-up of the Phase 2 PACE Trial (2015) (11)
Enhanced Bcr-Abl-specific antileukemic activity of arsenic trioxide (Trisenox) through glutathione-depletion in imatinib-resistant cells. (2007) (11)
The E3 ubiquitin ligase TRAF6 inhibits LPS-induced AKT activation in FLT3-ITD-positive MV4-11 AML cells (2013) (11)
Molecular Response According to Type of Preexisting BCR-ABL Mutations after Second Line Dasatinib Therapy in Chronic Phase CML Patients. (2007) (11)
Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer: a phase II study (2005) (11)
Development of AML with t(8;21)(q22;q22) and RUNX1-RUNX1T1 fusion following Philadelphia-negative clonal evolution during treatment of CML with Imatinib. (2009) (11)
The E3 ubiquitin ligase TRAF2 can contribute to TNF-α resistance in FLT3-ITD-positive AML cells. (2013) (11)
The BCR-ABLT 315 I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors , in a matched pair analysis (2013) (11)
A phase I study of INNO-406, a dual inhibitor of Abl and Lyn kinases, in adult patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) relapsed, refractory, or intolerant of imatinib (2007) (11)
Clonal T-LGL population mimicking leukemia in Felty’s syndrome—part of a continuous spectrum of T-LGL proliferations? (2013) (10)
Response to Dasatinib after Imatinib Failure According to Type of Preexisting BCR-ABL Mutations. (2006) (10)
What is the (p-) value of the P-value? (2016) (10)
Quantitative molecular methods to monitor the response of CML patients to interferon-alpha. (1996) (10)
Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor, in Patients with Chronic Myeloid Leukemia Carrying the T315I Mutation in a Phase 1 Trial (2018) (10)
No Differences in Molecular Relapse-Free Survival after Stopping Imatinib Treatment of Chronic Myeloid Leukemia Between Patients with Prior 4.5 Log Reduction (MR4.5) but Detectable and Patients with Undetectable Disease in the EURO-SKI Trial (2016) (10)
Chronic persistent parvovirus B19 bone marrow infection resulting in transfusion-dependent pure red cell aplasia in multiple myeloma after allogeneic haematopoietic stem cell transplantation and severe graft versus host disease (2017) (10)
Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study (2020) (10)
Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study (2013) (10)
Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib: Results from the ENESTFreedom study. (2016) (10)
Efficacy of antifungal prophylaxis with oral suspension posaconazole during induction chemotherapy of acute myeloid leukemia (2015) (10)
Activity of Bosutinib by Baseline and Emergent Mutation Status in Philadelphia Chromosome–Positive Leukemia Patients with Resistance or Intolerance to Other Tyrosine Kinase Inhibitors (2011) (10)
Weekend Drug Holiday of Dasatinib in CML Patients Not Tolerating Standard Dosing Regimens. Reducing Toxicity with Maintained Disease Control. (2009) (10)
Drug-induced lymphadenopathy with eosinophilia and renal failure mimicking lymphoma disease: dramatic onset of DRESS syndrome associated with antibiotic treatment (2011) (9)
Analysis of Glucose Profiles in Imatinib-Resistant or Intolerant Chronic Myelogenous Leukemia (CML) Patients (pts) Treated with Nilotinib: Lack of Correlation between Glucose Levels and Nilotinib Efficacy. (2007) (9)
Long Term Observation of CML Patients after Imatinib Resistance Associated with BCR-ABL Mutations. (2005) (9)
Safety and Efficacy of Dasatinib Versus Imatinib by Baseline Cardiovascular Comorbidity In Patients with Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of the DASISION Trial (2010) (9)
Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study (2021) (9)
Integration of mathematical model predictions into routine workflows to support clinical decision making in haematology (2020) (9)
Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity (2012) (9)
Cancer patients’ needs for virtues and physicians’ characteristics in physician-patient communication: a survey among patient representatives (2018) (9)
Importance of and Satisfaction with Information about Their Disease in Cancer Patients (2019) (9)
Molecular Surveillance of Chronic Myeloid Leukemia Patients in the Imatinib Era – Evaluation of Response and Resistance (2004) (9)
Molecular Responses with Ponatinib in Patients with Philadelphia Chromosome Positive (Ph+) Leukemia: Results From the PACE Trial (2012) (9)
Results of the European survey on the assessment of deep molecular response in chronic phase CML patients during tyrosine kinase inhibitor therapy (EUREKA registry) (2019) (9)
Mitomycin C and capecitabine in pretreated patients with metastatic gastric cancer: a multicenter phase II study (2014) (9)
Comparison of Treatment Strategies in Patients over 60 Years with AML: Final Analysis of a Prospective Randomized German AML Intergroup Study (2016) (9)
Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in the Imatinib-Era: Update on the Survival Outcome Following Allogeneic HSCT after Imatinib Failure; Results of the German CML Study IV (2008) (9)
5-Azacytidine modulates CpG methylation levels of EZH2 and NOTCH1 in myelodysplastic syndromes (2019) (9)
Complete remission after treatment with single-agent ofatumumab in a patient with high-risk leukemic mantle-cell lymphoma. (2013) (9)
Hematologic and Cytogenetic Response Dynamics to Nilotinib (AMN107) Depend on the Type of BCR-ABL Mutations in Patients with Chronic Myelogeneous Leukemia (CML) after Imatinib Failure. (2006) (9)
Extra-medullary recurrence of myeloid leukemia as myeloid sarcoma after allogeneic stem cell transplantation: impact of conditioning intensity (2020) (9)
Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network (2021) (8)
OPTIC primary analysis: A dose-optimization study of 3 starting doses of ponatinib (PON). (2021) (8)
Harmonization of BCR-ABL mRNA Quantification Using an Uniform Control Plasmid in 36 International Laboratories. (2005) (8)
Cancer Patients and the Internet: A Survey of the ‘Quality of Life’ Working Groups of the Arbeitsgemeinschaft für Internistische Onkologie and the Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie (2011) (8)
Dasatinib (Versus Imatinib) In Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of Safety and Efficacy by Use of Baseline Medications In the DASISION Trial (2010) (8)
Phase I study of gefitinib in combination with FOLFIRI as 2nd-/3rd-line treatment in patients with metastatic colorectal cancer (2005) (8)
Therapy-free remission in chronic myeloid leukemia: possible mechanism (2018) (8)
Durable remission with ruxolitinib in a chronic neutrophilic leukemia patient harboring a truncation and membrane proximal CSF3R compound mutation (2020) (8)
Correlation of Clinical Response to Nilotinib with BCR-ABL Mutation Status in Advanced Phase Chronic Myelogenous Leukemia (CML-AP) Patients with Imatinib-Resistance or Intolerance. (2007) (8)
PLCG1 is required for AML1-ETO leukemia stem cell self-renewal. (2021) (8)
Expression of interferon- a (IFN- a ) receptor 2c at diagnosis is associated with cytogenetic response in IFN- a –treated chronic myeloid leukemia (2001) (8)
Resistance to imatinib in chronic myelogenous leukemia: Mechanisms and clinical implications (2008) (8)
The Impact of Ponatinib Versus Allogeneic Stem Cell Transplant (SCT) on Outcomes in Patients with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) with the T315I Mutation (2015) (8)
Five-year results of the ponatinib phase II PACE trial in heavily pretreated CP-CML patients (pts). (2017) (8)
A prospective multicenter phase II trial of capecitabine plus oxaliplatin (CapOx) in advanced biliary system adenocarcinomas: The final results. (2006) (8)
Randomized Comparison of Primary Allogeneic Stem Cell Transplantation and Best Available Drug Treatment in Chronic Myeloid Leukemia. (2006) (8)
Optimizing tolerability of TKI therapy in CML. (2014) (8)
Detection and quantification of leukemia-specific rearrangements. (2002) (8)
The German competence network ‘Acute and chronic leukemias’ (2004) (8)
Comparison of "Log Reduction from Median Pretherapeutic Value" vs Ratio BCR-ABL/ABL to Express the Therapeutic Response in CML Patients. (2004) (8)
Alpha-fetoprotein expressing metastastic adenocarcinoma of the esophago-gastric junction responding favorably to capecitabine and oxaliplatin. (2009) (8)
Safety and Efficacy Study of Subcutaneous Homoharringtonine (SC HHT) in Imatinib (IM)-Resistant Chronic Myeloid Leukemia (CML) with the T315I Mutation - Initial Report of a Phase II Trial. (2007) (8)
Pegylated liposomal doxorubicin in combination with mitomycin C, infusional 5-fluorouracil and sodium folinic acid. A phase-I-study in patients with upper gastrointestinal cancer (2004) (8)
4-year results of the ponatinib phase II PACE trial in patients (pts) with heavily pretreated leukemia. (2016) (8)
Spotlight Imatinib: a model for signal transduction inhibitors (2002) (8)
Omacetaxine mepesuccinate prevents cytokine-dependent resistance to nilotinib in vitro: potential role of the common β-subunit c of cytokine receptors (2012) (8)
Response dynamics to nilotinib depend on the type of BCR-ABL mutations in patients with chronic myelogenous leukemia (CML) after imatinib failure (2007) (8)
Questions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisions (2018) (7)
Superior CMR-Rates with Tolerability-Adapted Imatinib 800 Mg Vs. 400 Mg Vs. 400 Mg + IFN In CML: The Randomized German CML-Study IV (2010) (7)
The prognostic significance of early molecular and cytogenetic response for long-term progression-free and overall survival in imatinib-treated chronic myeloid leukemia (CML). (2012) (7)
YBX1 mediates translation of oncogenic transcripts to control cell competition in AML (2021) (7)
Secondary Malignancies in CML Patients – Data From the German CML Study IV (2012) (7)
Fast and Quantitative Evaluation of Human Leukocyte Interaction with Aspergillus fumigatus Conidia by Flow Cytometry (2018) (7)
Nilotinib is associated with minimal cross intolerance to imatinib in patients with imatinib-intolerant chronic myelogenous leukemia (CML) in chronic phase (CP) (2007) (7)
ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia (2022) (7)
Phosphorylation-Dependent Differences in CXCR4-LASP1-AKT1 Interaction between Breast Cancer and Chronic Myeloid Leukemia (2020) (7)
The myeloproliferative neoplasm-associated JAK2 46/1 haplotype is not overrepresented in chronic myelogenous leukemia (2011) (7)
Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis (2017) (7)
Efficacy and safety of keratinocyte growth factor (palifermin) for prevention of oral mucositis in TBI-based allogeneic hematopoietic stem cell transplantation (2018) (7)
Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells (2018) (7)
Outcome By Mutation Status and Line of Treatment in Optic, a Dose-Ranging Study of 3 Starting Doses of Ponatinib in Patients with CP-CML (2020) (7)
An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase (2017) (7)
Knockout of LASP1 in CXCR4 expressing CML cells promotes cell persistence, proliferation and TKI resistance (2020) (7)
Impact of early molecular response to nilotinib (NIL) or imatinib (IM) on the long-term outcomes of newly diagnosed patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): Landmark analysis of 4-year (y) data from ENESTnd. (2013) (7)
Molecular Response at 3 Months On Nilotinib Therapy Predicts Response and Long-Term Outcomes in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP). (2009) (7)
Feasibility of Imatinib Combination Therapies in a Randomized Trial for Chronic Myeloid Leukemia: The German CML-Study IV - Pilot Phase. (2004) (7)
Only SETBP1 hotspot mutations are associated with refractory disease in myeloid malignancies (2017) (7)
Molecular Heterogeneity of the FIP1L1-PDGFRA Fusion Gene in Chronic Eosinophilic Leukemia (CEL) and Systemic Mastocytosis with Eosinophilia (SME): A Study of 43 Cases. (2004) (7)
A further milestone towards comprehensive standardization of quantitative RT-PCR protocols for leukemic fusion gene transcripts has been reached (2003) (7)
Clinical strategies to achieve an early and successful response to tyrosine kinase inhibitor therapy. (2009) (7)
Impact of Baseline Mutations on Response to Ponatinib and End of Treatment Mutation Analysis in Patients With Chronic Myeloid Leukemia (2014) (7)
Dose Modification Dynamics of Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) from the PACE and Optic Trials (2021) (7)
Hemophagocytic Lymphohistiocytosis in Adults (aHLH): Results from the German HLH Registry (2016) (7)
A Randomized Phase II Study of Single-Agent Imatinib Versus Chemotherapy Therapy in Elderly Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Including Analysis of Resistance Patterns. (2005) (7)
Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee (2022) (7)
Efficacy and Safety of Ponatinib According to Prior Approved Tyrosine Kinase Inhibitor (TKI) Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CP-CML): Results From the PACE Trial (2012) (7)
Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials (2021) (6)
Analysis of patients (pts) with chronic phase chronic myeloid leukemia (CML-CP) who develop pleural effusion on first-line dasatinib: Management and outcomes. (2011) (6)
BBR 3438, a novel 9-aza-anthrapyrazole, in patients with advanced gastric cancer: A phase II study group trial of the central European Society of Anticancer-Drug Research (CESAR) (2005) (6)
A Phase II Study of Nilotinib, a Novel Tyrosine Kinase Inhibitor Administered to Patients with Hypereosiniphilic Syndrome (HES). (2006) (6)
Nilotinib Vs Nilotinib Plus Pegylated Interferon-alpha2b Induction and Nilotinib or Pegylated Interferon-alpha2b Maintenance Therapy for Newly Diagnosed BCR-ABL+ Chronic Myeloid Leukemia Patients in Chronic Phase: Interim Analysis of the Tiger (CML V)-Study (2018) (6)
Impact of baseline mutations on response to ponatinib and end of treatment mutation analysis in patients with chronic myeloid leukemia. (2013) (6)
Comorbidity, Measured By The Charlson Index, Has No Negative Impact On Remission In Patients With Chronic Myeloid Leukemia: Results Of The Randomized CML-Study IV (2013) (6)
Paradoxical MAPK‐activation in response to treatment with tyrosine kinase inhibitors in CML: Flow cytometry loses track (2014) (6)
Response: too much BCR-ABL to live on, but too little BCR-ABL to die on? (2012) (6)
Suitability of the PAXgene™ system to stabilize bone marrow RNA in imatinib-resistant patients with chronic myeloid leukemia (2008) (6)
Molecular Response <1% BCR-ABL IS at 12 Months Is Associated with Improved Overall and Progression-Free Survival. the Randomized German CML-Study IV (2010) (6)
More Rapid Outgrowth Kinetics of BCR-ABL Mutations in Advanced Versus Newly Diagnosed Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Clinical-Translational Evidence for a Contributory Role of Non-Mutational Resistance Mechanisms. (2007) (6)
Minimal Residual Disease in Hematologic Malignancies (2004) (6)
Efficacy and safety of bosutinib (BOS) for Philadelphia chromosome–positive (Ph+) leukemia in older versus younger patients (pts). (2012) (6)
Cytogenetic and molecular characterization of simultaneous chronic and acute myelocytic leukemia. (2003) (6)
R-Mini-CHOP Versus R-Bendamustine As Primary Treatment for Diffuse Large B-Cell Lymphoma (DLBCL) in Elderly and Comorbid Patients (2014) (6)
Basic properties of a class of rational matrix differential equations (2001) (6)
The incidence of BCR-ABL mutations in patients (pts) with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CP) treated with nilotinib or imatinib in ENESTnd: 24-month follow-up. (2011) (6)
Chronische myeloische Leukämie (2019) (6)
Response and Outcomes to Nilotinib at 24 Months in Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) and Accelerated Phase (CML-AP) with and without BCR-ABL Mutations. (2009) (6)
Occurrence, Management, and Outcomes In Patients with Pleural Effusion During Dasatinib Treatment for Chronic-Phase Chronic Myeloid Leukemia (CML-CP) In the First-Line Setting: Analysis of the DASISION Trial (2010) (6)
Frailty impairs the feasibility of induction therapy but not of maintenance therapy in elderly myeloma patients: final results of the German Maintenance Study (GERMAIN) (2019) (6)
S1608 RUXOLITINIB PLUS POMALIDOMIDE IN MYELOFIBROSIS WITH ANEMIA: RESULTS FROM THE MPNSG-0212 COMBINATION TRIAL (NCT01644110) (2019) (6)
Bosutinib Vs Imatinib for Newly Diagnosed Chronic Myeloid Leukemia (CML) in the BFORE Trial: 18 Month Follow-up (2017) (6)
Higher Leukemia Free Survival after Post-Induction Hematopoietic Cell Transplantation Compared to Consolidation Therapy in Patients >60 Years with Acute Myelogenous Leukemia (AML): Report from the AML 2004 East German Study Group (OSHO) (2014) (6)
Treatment optimization by high-dose imatinib: Randomized comparison of imatinib 800 mg versus imatinib 400 mg {+/-} IFN in newly diagnosed BCR-ABL positive chronic phase (CP) CML: The German CML-study IV. (2010) (6)
Subcutaneous omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia (CML) patients (Pts) with the T315I mutation: Data from an ongoing phase II/III trial. (2016) (6)
Onkologische Kardiologie (2020) (6)
Quantification of BCR-ABL with Digital PCR Results in a Significantly Lower Rate of Deep Molecular Responses When Compared to RT-qPCR in CML Patients Treated in the ENEST1st Trial (2015) (6)
Efficacy and Safety Following Dose Reduction of Bosutinib or Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia: Analysis of the Phase 3 BFORE Trial (2018) (6)
Impact Of Baseline (BL) Mutations, Including Low-Level and Compound Mutations, On Ponatinib Response and End Of Treatment (EOT) Mutation Analysis In Patients (Pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML) (2013) (6)
Stability of Conversion Factors for BCR-ABL Monitoring - Implications for the Frequency of Validation Rounds (2010) (6)
Ponatinib after failure of second‐generation tyrosine kinase inhibitor in resistant chronic‐phase chronic myeloid leukemia (2022) (6)
Safety issues and management of toxicities associated with new treatments for multiple myeloma (2017) (6)
Stable molecular remission induced by imatinib mesylate (STI571) in a patient with CML lymphoid blast crisis relapsing after allogeneic stem cell transplantation (2003) (6)
Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia (2021) (6)
Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of TP53 mutations – a registry based analysis (2021) (6)
Gangrene of the toes in a patient with chronic myelogenous leukemia after long-term hydroxyurea therapy (2002) (6)
Dasatinib Versus Imatinib in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Not Achieved an Optimal Response to 3 Months of Imatinib Therapy: Dascern (2018) (5)
Good Prognosis of CML Patients with Clonal Cytogenetic Abnormalities in Ph-Negative Cells. (2005) (5)
Complete Molecular Remission (CMR 4.5) of CML Is Induced Faster by Dose – Optimized Imatinib and Predicts Better Survival - Results From the Randomized CML-Study IV (2012) (5)
Clinical Impact Of Dose Modification On Response To Ponatinib In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) (2013) (5)
Impact of Allogeneic Stem Cell Transplantation as Salvage Therapy After T315I Mutation Detection in Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL) Patients. (2009) (5)
Aktuelle Therapiekonzepte bei chronischer myeloischer Leukämie Die Studie IV der Deutschen CML-Studiengruppe (2002) (5)
AraC-based pharmacotherapy of chronic myeloid leukaemia (2001) (5)
Bosutinib or Imatinib in Older Vs Younger Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Phase 3 BFORE Trial (2018) (5)
A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib resistant and intolerant patients (pts) with chronic myelogenous leukemia (CML) in chronic phase (CP). (2006) (5)
Deep molecular response in chronic myeloid leukemia (2016) (5)
Expression of the LH2 gene in chronic myeloid leukaemia cells. (1996) (5)
The long term outcome of the patients with chronic myeloid leukemia (CML) who have achieved complete cytogenetic response (CCgR) to interferon-alpha (IFN alpha). A collaborative European study of 317 cases. (2001) (5)
Prognostic Factors in Chronic Myeloid Leukemia (CML) (2008) (5)
Seven-Year (yr) Follow-up of Patients (pts) with Imatinib-Resistant or -Intolerant Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Receiving Dasatinib in Study CA180-034, Final Study Results (2014) (5)
Selektive Hemmung von Tyrosinkinasen als neues therapeutisches Prinzip in der Onkologie (2001) (5)
Case report: false positive elevated serum‐galactomannan levels after autologous hematopoietic stem cell transplantation caused by oral nutritional supplements (2016) (5)
Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations (2022) (5)
Outcome of patients with CML after SCT in the era of tyrosine kinase inhibitors (2012) (5)
S884 COMBINATION OF ASCIMINIB PLUS NILOTINIB (NIL) OR DASATINIB (DAS) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA (CML): RESULTS FROM A PHASE 1 STUDY (2019) (5)
Optimizing Early Prediction Of Outcome In CML Using The Exact Decline Of BCR-ABL Transcript Levels Within 3 Months Of Imatinib Treatment As a Prognostic Marker (2013) (5)
Efficacy and feasibility of cyclophosphamide combined with intermediate- dose or high-dose cytarabine for relapsed and refractory acute myeloid leukemia (AML) (2014) (5)
Dasatinib efficacy by dosing schedule across individual baseline BCR-ABL mutations in chronic phase chronic myelogenous leukemia (CML-CP) after imatinib failure (2008) (5)
High BCR-ABL/GUSIS Levels At Diagnosis Are Associated With Unfavorable Responses To Imatinib (2013) (5)
CML - Not only BCR-ABL1 matters. (2020) (5)
Early Detection of Imminent Hematologic Relapse Due to BCR-ABL Kinase Domain Mutations in CML Patients on Imatinib Therapy by D-HPLC. (2005) (5)
Not all cancer patients with an interest in CAM are the same. Differences between patients with a CAM interest prior to the cancer diagnosis and those with first-time interest since diagnosis. (2019) (5)
Ponatinib In Heavily Pretreated Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML): Management Of Adverse Events (AEs) (2013) (5)
Genomic Instability in Context of the Chromosomal Theory (2008) (5)
Phase I trial of docetaxel, oxaliplatin and capecitabine (TEX) in patients with metastatic gastric cancer. (2006) (5)
Incidence, Comorbidity and Treatment Survey of Chronic Myeoloid Leukemia in Germany. (2007) (5)
Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: 12-Month Patient-Reported Outcomes from the BFORE Trial (2017) (5)
Molecular investigation of secondary chronic myeloid leukemia. (1996) (5)
A case of Brooke–Spiegler syndrome with a novel mutation in the CYLD gene in a patient with aggressive non-Hodgkin’s lymphoma (2016) (5)
[Chronic myeloproliferative diseases. Diagnosis and therapy]. (2003) (5)
Optimaization of Imatinib Therapy by Combination. 5 Year Survival and Response Results of the Pilot Phase of the Randomized German CML STUDY IV. (2009) (5)
[Chronic Myelogenous Leukemia]. (2018) (5)
Hämatologische Nebenwirkungen der Tyrosinkinaseinhibition mit Imatinib (2006) (5)
Cross-Intolerance with Bosutinib after Prior Tyrosine Kinase Inhibitors in Patients with Chronic Phase Chronic Myeloid Leukemia: BYOND Phase 4 Study (2019) (5)
Ruxolitinib Plus Pomalidomide in Myelofibrosis: Updated Results from the Mpnsg-0212 Trial (NCT01644110) (2016) (5)
Validation of the International Scale for Measurement of BCR-ABL by RQ-PCR Based on Deriving Laboratory-Specific Conversion Factors. (2007) (5)
A phase 1 study of IDH305 in patients with IDH1R132-mutant acute myeloid leukemia or myelodysplastic syndrome (2022) (5)
Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia (2021) (5)
Successful unrelated allogeneic stem cell transplantation after treatment of lymphoid blast crisis CML with imatinib and imatinib-containing conditioning regimen in a 16-year-old male (2003) (5)
Managing myeloproliferative neoplasms evidence based on the ELN treatment recommendations 2018 (2018) (5)
Response to nilotinib in chronic myelogenous leukemia patients in chronic phase (CML-CP) according to BCR-ABL mutations at baseline #7060 (2008) (4)
S155: EFFICACY AND SAFETY RESULTS FROM ASCEMBL, A PHASE 3 STUDY OF ASCIMINIB VS BOSUTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE AFTER ≥2 PRIOR TYROSINE KINASE INHIBITORS: WK 96 UPDATE (2022) (4)
Interferon in chronic myeloid leukemia (1993) (4)
Sustained Molecular Responses with Interferon α2a Maintenance Therapy after Imatinib Plus IFN Induction Treatment for Chronic Phase Chronic Myelogenous Leukemia. (2007) (4)
Inhibition of bone morphogenetic protein signaling reduces viability, growth and migratory potential of non-small cell lung carcinoma cells (2019) (4)
Frequent Inactivating Mutations of TET2 and CBL Are Associated with Acquired Uniparental Disomy in Atypical Chronic Myeloid Leukemia and Related Disorders. (2009) (4)
[Current therapy concepts in chronic myeloid leukemia. Study IV of the German CML Study Group]. (2002) (4)
Randomized studies with interferon in chronic myelogenous leukemia (CML) and comparative molecular aspects. German CML Study Group. (1997) (4)
CHRONIC MYELOID LEUKEMIA PATIENTS WERE NOT DIFFERENT IN MOLECULAR RELAPSE AFTER STOPPING IMATINIB IN MR4 WHETHER RESIDUAL DISEASE WAS DETECTED OR NOT - WHEN ADJUSTING FOR NUMBER OF CONTROL TRANSCRIPTS (2017) (4)
Efficacy of Bosutinib in Imatinib-Resistant Vs Dasatinib/Nilotinib-Resistant Chronic Phase Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study (2019) (4)
Explaining survival differences between two consecutive studies with allogeneic stem cell transplantation in patients with chronic myeloid leukemia (2014) (4)
[Hematological side effects of tyrosine kinase inhibition using imatinib]. (2006) (4)
Correlation of Minimal Tumor Dose and Histopathological Regression of Rectal Cancer after Neoadjuvant Combined Radio-chemo-immunotherapy - Results of a Prospective Phase I/II Study (Cetuximab Capiri-RT) (2008) (4)
A Multicenter Phase-Ib/II Study of Ruxolitinib/Pomalidomide Combination Therapy in Patients with Primary and Secondary Myelofibrosis: Safety Data from the Mpnsg-0212 Trial (NCT01644110) (2014) (4)
Key Data Elements in Myeloid Leukemia (2016) (4)
Achieving Early Landmark Response Is Predictive of Outcomes in Heavily Pretreated Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib (2014) (4)
Concept, Feasibility and Results of the Randomized Comparison of Imatinib Combination Therapies for Chronic Myeloid Leukemia: The German CML-Study IV. (2005) (4)
Sensitivity, Reproducibility and Clinical Utility Of Next-Generation Sequencing (NGS) for BCR-ABL1 Kinase Domain Mutation Screening: Results From The CML Work Package Of The Iron-II (Interlaboratory RObustness Of Next-Generation Sequencing) International Study (2013) (4)
A Phase IIIb Multicentre Open-Label Study of Nilotinib in Adult Patients with Newly Diagnosed BCR-ABL Positive Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A European Clinical Initiative with EUTOS Collaboration for Standardisation of Molecular Remission (2011) (4)
Combination of Asciminib+Nilotinib or Asciminib+Dasatinib in Previously Treated Chronic Myeloid Leukemia (CML) Patients: Phase 1 Study Results (2019) (4)
A Phase-II-Study To Evaluate Efficacy and Safety of Imatinib in Eosinophilia-Associated Myeloproliferative Disorders and Idiopathic Hypereosinophilic Syndrome. (2006) (4)
A phase II study of AMN107, a novel tyrosine kinase inhibitor, administered to patients (pts) with systemic mastocytosis (SM). (2006) (4)
Comparison of two dose levels of cyclophosphamide for successful stem cell mobilization in myeloma patients (2016) (4)
Real-time Quantification of BCR-ABL mRNA Transcripts Using the LightCycler-t ( 9 ; 22 ) Quantification Kit (2000) (4)
Monitoring the efficiency of interferon-alpha therapy in chronic myelogenous leukemia (CML) patients by competitive polymerase chain reaction. (1997) (4)
Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors (TKIs) in patients (pts) with Philadelphia chromosome–positive (Ph+) leukemia: Phase 1/2 study update. (2018) (4)
Interferon Alpha 2a (IFN) Maintenance Therapy After Imatinib Plus IFN Induction Therapy in Chronic Myeloid Leukemia (CML) Induces Stable Long-Term Molecular Remissions and Is Associated with Increased Proteinase 3 (PR3) Expression and the Presence of PR1-Specific T-Cells. (2009) (4)
European leukemianet-integration of the leading national leukemia networks (CML, AML, ALL, CLL, MDS, CMPD) another interdisciplinary partner groups in Europe (2007) (4)
First Results from a Collaborative Initiative To Develop an International Scale for the Measurement of BCR-ABL by RQ-PCR Based on Deriving Laboratory-Specific Conversion Factors. (2006) (4)
Harmonized Testing for BCR-ABL Kinase Domain Mutations In CML: Results of a Survey and First Control Round within 28 National Reference Laboratories In Europe (2010) (4)
Pomalidomide In MPN–associated Myelofibrosis With Cytopenia: Results Of The Mpnsg 01-09 Study (2013) (4)
Adverse Events (AE) Under Imatinib Treatment Over 10 Years: Results From 1501 Patients Of The Randomized CML-Study IV (2013) (4)
Chronic myelogenous leukemia: ESMO clinical recommendations for the diagnosis, treatment and follow-up. (2008) (4)
COMBINATION THERAPY OF POMALIDOMIDE PLUS RUXOLITINIB IN MYELOFIBROSIS: RESULTS FROM COHORT 1 OF THE MPNSG-0212 TRIAL (NCT01644110) (2017) (4)
Long-term treatment-free remission (TFR) following frontline (1L) nilotinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): ENESTfreedom 144-wk results. (2018) (4)
Modelling cost effectiveness of horse antithymocyte globulin for treating severe aplastic anaemia in Germany (2013) (4)
The Presence of the BCR-ABL T315I Mutation In Chronic Phase Chronic Myelogenous Leukemia Resistant to Tyrosine Kinase Inhibitors Profoundly Compromises Overall Survival and Progression Free Survival. Preliminary Results of a Matched Pair Analysis. (2010) (4)
Minimal Residual Disease in Hematological Malignancies (2004) (4)
Analysis of Molecular Data and the Emergence of Mutations for Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) Patients Treated with Dasatinib After Imatinib Failure. (2009) (4)
Functional acute liver failure after treatment with pegylated asparaginase in a patient with acute lymphoblastic leukemia: potential impact of plasmapheresis (2016) (4)
An independent review of arterial occlusive events (AOEs) in the ponatinib (PON) phase II PACE trial (NCT01207440) in patients (pts) with Ph+ leukemia. (2020) (4)
BCR-ABL P-Loop Deletion Detected in Imatinib-Resistant CML Patients Corresponds to Splice Variant Associated with L248V Point Mutation, Retains BCR-ABL Kinase Activity, and Responds to Dasatinib Treatment. (2006) (4)
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, Stuttgart, 29. September-3. Oktober 2017: Abstracts (2017) (4)
Chronische myeloische Leukämie (2012) (4)
Multizentrische prospektive kontrollierte Studie zur Therapie der chronisch myeloischen Leukämie. Vergleich von Busulfan, Hydroxyurea und Interferon alpha (Stand April 1990) (1991) (4)
Safety and Efficacy Of Bendamustine In Patients With Aggressive Non-Hodgkin Lymphomas (NHL) (2013) (3)
The Polycistronic miRNA Cluster miR-17-92 Is Over-Expressed in Early Phase Chronic Myeloid Leukemia (CML) CD34+ Cells. (2006) (3)
A multicenter phase II study of capecitabine plus oxaliplatin (CapOx) in advanced biliary system adenocarcinomas. (2004) (3)
A multicenter, randomized phase III study of asciminib (ABL001) versus bosutinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with ≥2 tyrosine kinase inhibitors (TKIs). (2019) (3)
Histone demethylase KDM4C is a functional dependency in JAK2-mutated neoplasms (2022) (3)
A phase II trial of second-line irinotecan and capecitabine after failure of first line infusional 5-fluorouracil and folinic acid in metastatic colorectal cancer (MCRC). (2004) (3)
Towards a Better Understanding of Epidemiology, Survival and Treatment in Myeloproliferative Neoplasms: Results of the European Leukemianet Registry (ERNEST study) (2014) (3)
Time-Related Interpretation of Molecular Response Levels According to Long Term Overall and Progression-Free Survival of CML Patients on First-Line Imatinib Treatment (2011) (3)
Abstract 5164: Selectively enriched CD90/Thy-1-positive cells from peripheral blood allow discrimination of patients and further analysis on a single cell level (2011) (3)
Polymethine Dye-Functionalized Nanoparticles for Targeting CML Stem Cells (2020) (3)
High-Risk Additional Chromosomal Abnormalities in CML Herald Death By Blast Crisis Already at Low Blast Levels (2019) (3)
Reply to H. Kantarjian et al. (2014) (3)
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL (2023) (3)
A multicenter phase II study of capecitabine plus oxaliplatin (CapOx) in advanced biliary system adenocarcinomas (2004) (3)
Expression of transketolase-like gene 1 (TKTL1) depends on disease phase in patients with chronic myeloid leukaemia (CML) (2014) (3)
“Clinical and Molecular Heterogeneity of Eosinophilia-Associated Myeloproliferative Neoplasms with a Translocation t(5;12)”. (2009) (3)
CML-047 Post Hoc Analysis of Responses to Ponatinib in Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML) by Baseline BCR::ABL1 Level and Baseline Mutation Status in the OPTIC Trial. (2021) (3)
Association of early molecular response to nilotinib with probability of cytogenetic response in chronic myeloid leukemia patients (pts) who fail imatinib. (2010) (3)
Oral Asciminib (ABL001) vs Bosutinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Received ≥ 2 Prior Tyrosine Kinase Inhibitors (TKIs): A Multicenter, Open-Label, Randomized, Phase 3 Study (2017) (3)
Phase I and pharmacokinetic study of the oral tris-(8-quinolinolato)gallium(III) complex (FFC11, KP46) in patients with solid tumors - a study of the CESAR Central European Society for Anticancer Drug Research - EWIV (2005) (3)
Molecularly Defined Clonal Evolution in Patients with Chronic Myeloid Leukemia Independent of the BCR-ABL Status (2014) (3)
Convergence and existence results for continuous- and discrete-time Riccati equations (2002) (3)
Interferon alpha for essential thrombocythemia during 34 high-risk pregnancies: outcome and safety (2020) (3)
Comparing the Prognostic Significance of Early Predictors of Survival in Chronic Myeloid Leukemia (CML) Treated with Imatinib - an Analysis of the Randomized CML-Study IV (2014) (3)
[Acute leukemia in adults]. (2015) (3)
Lower gastrointestinal bleeding in a patient with Crohn’s disease and plasma cell leukemia in remission (2015) (3)
New perspectives with interferon alpha. The German CML study group experience. (1994) (3)
Analyses of Predictors of Durable Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase Following Frontline or Second-Line Nilotinib (2019) (3)
CML-114: Interim Analysis from the OPTIC Trial - A Dose-Ranging Study of 3 Starting Doses of Ponatinib (2020) (3)
Centrosome Aberrations, Disturbed Mitotic Spindle Formation and G1 Arrest in Normal and Leukemic Cells Treated with the SRC/ABL Inhibitor Dasatinib. (2006) (3)
Reply to K.R. Hoffman. (2017) (3)
FINAL Analysis of a PAN European STOP Tyrosine Kinase Inhibitor Trial in Chronic Myeloid Leukemia : The EURO-SKI Study (2021) (3)
Der selektive Tyrosinkinase-Inhibitor Imatinib (STI571) bei hämatologischen und onkologischen Erkrankungen (2002) (3)
Detection of community‐acquired respiratory viruses in allogeneic stem‐cell transplant recipients and controls—A prospective cohort study (2020) (3)
Secondary imatinib resistance associated with an aberrant bcr-abl fusion gene (2004) (3)
PF409 DURABILITY AND IMPACT ON QUALITY OF LIFE OF TREATMENT-FREE REMISSION (TFR) IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) AFTER STOPPING FRONTLINE (1L) NILOTINIB: ENESTFREEDOM 192-WK RESULTS (2019) (3)
Arterial Occlusive Events (AOEs) in the Phase 2 Ponatinib PACE Trial: 5-Year Update in Heavily Treated Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) (2017) (3)
4-Year Results from the Pivotal Phase 2 PACE Trial: Efficacy and Safety in Heavily Pretreated Leukemia Patients (2016) (3)
CML Patients In Clinical Trials Represent Fairly Well The General Population Of CML Patients: A Comparative Analysis Of 5803 Patients From The EUTOS Registry (2013) (3)
Modulation of FLT3-ITD Localization and Targeting of Distinct Downstream Signaling Pathways as Potential Strategies to Overcome FLT3-Inhibitor Resistance (2021) (3)
Molecular-defined clonal evolution in patients with chronic myeloid leukemia who were exposed to ionizing radiation following the Chernobyl nuclear disaster (2019) (3)
Efficacy and Safety of Ponatinib in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) According to the Extent of Treatment with Prior Tyrosine Kinase Inhibitors (TKIs): Final (5-Year) Results of the PACE Study (2017) (3)
Transient response to imatinib in an atypical chronic myeloproliferative disease associated with ins(9;4)(q34;q21q31) and a CDK5RAP2-PDGFRA fusion gene (2005) (3)
Assessment of Early Cytogenetic Response As a Predictor of Long-Term Clinical Outcomes in a Phase 1/2 Study of Bosutinib in Chronic Phase CML. (2012) (3)
Combination of Asciminib, a Novel and Specific BCR-ABL1 Inhibitor, Plus Imatinib in Previously Treated Chronic Myeloid Leukemia (CML) Patients: Phase 1 Study Results (2019) (3)
Vorwort des DGHO-Vorstandes (2022) (3)
Therapie der chronischen myeloischen Leukämie 2004 (2004) (3)
The Incidence of BCR-ABL Mutations and Their Impact on Outcome in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib or Imatinib in ENESTnd: 36-Month Follow-up (2011) (3)
Melphalan 200 mg/m2 does not increase toxicity and improves survival in comparison to reduced doses of melphalan in multiple myeloma patients (2020) (3)
Primary results of the phase 4 BYOND study of bosutinib (BOS) for pretreated chronic phase (CP) chronic myeloid leukemia (CML). (2019) (3)
CML-466 Asciminib Provides Durable Molecular Responses in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With the T315I Mutation: Updated Efficacy and Safety Data From a Phase I Trial. (2022) (3)
BCR-ABL kinase domain mutations on second line dasatinib or nilotinib therapy in chronic myeloid leukemia patients after imatinib failure : a cooperative evaluation of different detection methods (2009) (3)
Placental Growth Factor: a Novel, Stromal-Derived Target in Human CML. (2009) (3)
Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma (2010) (3)
Downregulation of the Common Cytokine Receptor Subunit Beta c by Omacetaxine in CML: A Potential Molecular Mechanism to Overcome Cytokine-Mediated Resistance against BCR-ABL-Inhibitors. (2009) (3)
Treatment-free remission (TFR) following frontline (1L) nilotinib (NIL) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): 192-week data from the ENESTfreedom study. (2019) (3)
Chronische myeloische Leukämie (2009) (3)
ASSESSMENT OF IMATINIB 400MG AS FIRST LINE TREATMENT OF CHRONIC MYELOID LEUKEMIA: 10-YEAR SURVIVAL RESULTS OF THE RANDOMIZED CML STUDY IV (2017) (2)
Blood platelet calcium content and aggregation behaviour in myeloproliferative disorders and secondary thrombocytosis. (1988) (2)
NK cell dynamics and association with molecular response in early chronic phase chronic myelogenous leukemia (CML-CP) patients treated with nilotinib (2017) (2)
Successful treatment of neutropenic MRSA bacteremia with septic superior vena cava thrombus and cerebral embolism using high-dose daptomycin (2015) (2)
Bcr-Abl Tyrosine Kinase Domain Mutations Both Pre-Exist and Develop during Imatinib Treatment and Are Responsible for Resistance in Patients with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL). (2006) (2)
Individual molecular response evaluation on both DNA and mRNA BCR-ABL1 level diminished differences in time to molecular response achievement between CML patients with E13A2 vs E14A2 transcript type (2020) (2)
Absolute Quantification of Mutant T315I BCR-ABL Transcripts At 6 Months Identifies Imatinib Resistant CML Patients with a Low Probability to Achieve MMR After 12 Months on Second Line Tyrosine Kinase Therapy (2011) (2)
Second Line Therapy with Second Generation TKI After Intolerance to Imatinib Based Treatments Showed High Overall Survival in Contrast to Second Line Therapy After Resistance; Results of the Randomized CML Study IV (2011) (2)
High BCR-ABL/GUSIS Levels at Diagnosis Are Associated with Unfavorable Responses to Standard Dose Imatinib (2015) (2)
Diagnostik und Therapie der chronischen myeloischen Leukämie (2002) (2)
Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial (2007) (2)
PF415 EFFICACY AND SAFETY FOLLOWING DOSE REDUCTION OF BOSUTINIB IN PREVIOUSLY TREATED PATIENTS WITH CHRONIC MYELOID LEUKEMIA: ANALYSIS OF THE PHASE 4 BYOND TRIAL (2019) (2)
Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis (2021) (2)
BCL6 Is Required for the Maintenance of Leukemia-Initiating Cells In Chronic Myeloid Leukemia (2010) (2)
[Selective tyrosine kinase inhibitor imatinib (STI571) in haematological and oncological disease]. (2002) (2)
[Therapy of chronic myelogenous leukemia in 2004]. (2004) (2)
Polymorphic variation at the STAT5 locus is associated with the response of CML patients to interferon alpha (2007) (2)
Six Year Follow-Up Results of a Phase II Study of Imatinib in Late Chronic Phase (L-CP) Chronic Myeloid Leukemia (CML) Post Interferon-A (IFN) Refractoriness/Intolerance. (2006) (2)
Early molecular response to nilotinib in patients who failed imatinib is associated with a higher probability of cytogenetic response in chronic myeloid leukemia (CML) (2010) (2)
Correction: Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study (2020) (2)
Sex-Disaggregated Analysis of Biology, Treatment Tolerability, and Outcome of Multiple Myeloma in a German Cohort (2022) (2)
Impact of early landmark responses with ponatinib on 4-yr outcomes in CP-CML patients (pts) in PACE, a pivotal phase II trial. (2017) (2)
HHV-6 encephalitis in a non-transplanted adult acute myeloid leukemia patient (2021) (2)
Treosulfan plus fludarabine versus TEAM as conditioning treatment before autologous stem cell transplantation for B-cell Non-Hodgkin lymphoma (2022) (2)
Prognostic Impact of mRNA Expression Levels of HER1–4 (ERBB1–4) in Patients with Locally Advanced Rectal Cancer (2016) (2)
Development and evaluation of a secondary reference panel for BCR-ABL1 quanti ﬁ cation on the International Scale (2016) (2)
Capecitabine (cape)-associated hand-foot skin reaction (HFS) as a clinical predictor of improved survival in patients (pts) with colorectal cancer. (2012) (2)
Molecular Long-Term Surveillance of CML Patients on Imatinib Therapy. Follow-Up of German Patients Treated within the IRIS Trial. (2004) (2)
Measurement of piperacillin plasma concentrations in cancer patients with suspected infection (2017) (2)
A randomized phase II, open-label trial of orally administered SAR302503 in patients with polycythemia vera (PV) or essential thrombocythemia (ET) who are resistant or intolerant to hydroxyurea. (2012) (2)
European multicenter experience on idiopathic hypereosinophilic syndrome (HES) with FIP1L1-PDGFRA rearrangement treated with Imatinib (2004) (2)
Effect of dose-optimized imatinib (IM) 800 mg on deep molecular responses (CMR 4.5) and prediction of survival: Results from the randomized CML-study IV. (2013) (2)
Efficacy and Safety of Front-Line Nilotinib Treatment and Discontinuation in Older Patients (≥65 years) with Chronic Myeloid Leukemia in Chronic Phase Who Have Achieved MR4.5: Results from ENESTfreedom (2020) (2)
TKI discontinuation in CML: how do we make more patients eligible? How do we increase the chances of a successful treatment-free remission? (2021) (2)
Short‐Term Application of Magnetic Core‐Shell Nanoparticles—Effect on Immune Cells (2010) (2)
S883 COMBINATION THERAPY USING ASCIMINIB PLUS IMATINIB (IMA) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA (CML): RESULTS FROM A PHASE 1 STUDY (2019) (2)
The incidental discovery of a constitutional trisomy 21 mosaicism in an adult female with myelodysplastic/myeloproliferative neoplasm (2021) (2)
Response dynamics of pediatric patients with chronic myeloid leukemia on imatinib therapy (2017) (2)
Assessment of Molecular Response in CML Patients with Atypical BCR-ABL Tanscripts. Recommendations By the EUTOS Collaboration (2016) (2)
Interferon in chronic myeloid leukemia. A workshop report. (1993) (2)
Chronic Myelogeneous Leukemia (2015) (2)
Correction: High-risk additional chromosomal abnormalities at low blast counts herald death by CML (2020) (2)
Author Correction: Metabolic gatekeeper function of B-lymphoid transcription factors (2018) (2)
Clinical Characteristics and Outcome in IDH1/2 Mutant AML Patients - Analysis of 3898 Newly Diagnosed Patients with Acute Myeloid Leukemia (2018) (2)
Major route additional chromosomal aberrations (ACA) precede increase of blasts in chronic myeloid leukemia (CML) independent of therapy. An analysis of CML studies III, IIIA and IV (2016) (2)
Therapie der chronischen myeloischen Leukämie (2019) (2)
Response to Ho-Wan Ip and Chi-Chiu (2015) (2)
Novel constitutional t(2;12)(q21;q22) in a patient with t(9;22)-negative chronic myelocytic leukemia. (2003) (2)
ENESTfreedom and ENESTop Update: Durable Treatment-Free Remission (TFR) at 96 Weeks after Nilotinib Treatment Cessation in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) (2017) (2)
Dasatinib compared to imatinib in patients with newly diagnosedchronic-phase chronic myelogenous leukemia (CML-CP): resultsfrom the randomized phase 3 dasision tria (2010) (2)
Evaluation of the Benefit/Risk Profile of Ponatinib in CP-CML Patients over Time: 4-Year Follow-up of the Phase 2 PACE Study (2015) (2)
Impact of Treatment Cessation on Overall Disease Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Attempting Treatment-Free Remission (TFR): Findings from Enestfreedom and Enestop (2017) (2)
Patients with Chronic Myeloid Leukemia In Chronic Phase Carrying More Than One BCR-ABL Kinase Domain Mutation Exhibit Poorer Response Rates and Outcomes to Second-Line Dasatinib Compared to Those with No or Only One BCR-ABL Mutation (2010) (2)
The EHA Research Roadmap: Malignant Myeloid Diseases (2021) (2)
EZH2 Mutations and Impact on Clinical Outcome Analyzed in 1604 Patients with Acute Myeloid Leukemia (2018) (2)
Chronische myeloische Leukämie (2011) (2)
Efficacy and safety of ponatinib in heavily pretreated leukemia patients in the PACE trial: 3-year results. (2015) (2)
Phase 2, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Patients with Myeloid/Lymphoid Neoplasms with Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement (2017) (2)
Ponatinib in Heavily Pretreated Leukemia: 3-Year PACE Trial Results (2015) (2)
Safety and Efficacy of the mTOR Inhibitor Everolimus as Early Interventional Replacement for Calcineurin Inhibitors In Graft-Versus-Host Disease (GvHD) Prophylaxis After Allogeneic Stem Cell Transplantation (2010) (2)
Evolution of Blast Crisis (BC) in Chronic Myeloid Leukemia (CML) in the Imatinib-Era: A Rare Event with High Proportions of Low Risk Patients and of Early Bc; Need for Rapid Detection. Results of the German CML Study IV. (2009) (2)
Analysis of Bone Marrow Microenviroment Factors As Early Markers of Response in Patients with Newly Diagnosed Bcr-Abl Positive CML in Chronic Phase Treated with Nilotinib. (2012) (2)
Hemophagocytic lymphohistiocytosis (HLH): a cytokine storm disorder mimicking sepsis and a diagnostic pitfall on intensive care units (2017) (2)
Diagnostik und Therapie der CML (1998) (2)
Bosutinib as Third-Line Treatment for Chronic Phase Chronic Myeloid Leukemia Following Failure of Second-Line Therapy with Dasatinib or Nilotinib (2010) (2)
Imatinib and Beyond – Targeting Activated Tyrosine Kinases in Myeloproliferative Disorders (2012) (2)
[Selective inhibition of tyrosine kinases - a new therapeutic principle in oncology]. (2001) (2)
management and outcome of Cml-blast crisis: Results from the randomized Cml study Iv : V907 (2014) (2)
Chronische myeloische Leukämie mit Management-Empfehlungen des European LeukemiaNet (2006) (2)
Monitoring of Residual Disease in Patients with Chronic Myelogenous Leukemia Using Specific Fluorescent Hybridization Probes for Real-Time Quantitative RT-PCR (2001) (2)
Phase I/II trial of capecitabine (Cap) and oxaliplatin (Ox) in combination with bevacizumab (Bev) and imatinib (Ima) in patients with metastatic colorectal cancer (CRC): AIO KRK 0205. (2011) (2)
The impact of specific cytokine directed treatment on severe COVID-19 (2021) (2)
CML-417: ASCEMBL Phase 3 Health-Related Quality of Life (HRQL) Comparison of Asciminib and Bosutinib for Patients with Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated with 2 or More Tyrosine Kinase Inhibitors (TKI) (2021) (2)
Deep Molecular Responses In Patients With Newly Diagnosed Chronic Myeloid Leukemia Receiving Nilotinib As Assessed Within The EUTOS Laboratory Network In The ENEST1st Study (2013) (2)
A Multicenter, Randomized Phase 3 Study of Asciminib (ABL001) vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 TKIs (2019) (2)
Pomalidomide in Myelofibrosis with Cytopenia: First Results of the Mpnsg 01–09 Study (ClinicalTrials.gov Identifier: NCT00949364). (2012) (2)
Targeting Rac2 - Mitochondrial Respiratory Chain Complex III Signaling to Prevent Genomic Instability in Leukemia Stem and Progenitor Cells (2011) (2)
Negatively charged magnetic nanoparticles pass the blood-placenta barrier under continuous flow conditions in a time-dependent manner (2021) (2)
OPTIC-2L: a Superiority Trial of Two Lower Doses of Ponatinib Versus Standard Dose Nilotinib in Second-Line Chronic Phase CML (2016) (2)
Impact of Balanced or Unbalanced Karyotype At Diagnosis On Prognosis of CML: Long-Term Observation From 1346 Patients of the Randomized CML Study IV (2012) (2)
Therapy with Imatinib In Elderly CML Patients (>65years): Results of the German CML-Study IV. (2010) (2)
Induction Therapy for AML with 90 Mg/m² Daunorubicin Results in Higher Troponin T Serum Levels in Comparison to Treatment with 60 Mg/m² Daunorubicin (2017) (2)
Die hämophagozytische Lymphohistiozytose (HLH) und das Makrophagenaktivierungssyndrom (MAS): Klinisches Erscheinungsbild und Diagnostik (2013) (2)
Spätfolgen der allogenen Blutstammzelltransplantation (2015) (1)
Leriche’s syndrome and Löffler endocarditis in a 30-year-old patient presenting with hypereosinophilic syndrome (2011) (1)
Axl Represents a Therapeutic Target In T315I-Mutated and WT Chronic Myeloid Leukemia (2013) (1)
10-year survival with imatinib: final evaluation of randomized CML-study (2017) (1)
EPIC: A phase III randomized, open-label study of ponatinib versus imatinib in adult patients with newly diagnosed chronic myeloid leukemia in chronic phase. (2013) (1)
Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase: the ASC4FIRST phase III trial. (2022) (1)
GATA2 Expression Level in Chronic Myeloid Leukemia (CML) Patients Correlates with Their Prognostic Scores and Is Associated with Disease Stage at Diagnosis (2015) (1)
Pretreatment Expression Levels of MDR1 and OCT-1 Predict Response to First Line Imatinib Treatment In Chronic Phase CML Patients (2010) (1)
Outcome of patients with relapsed or refractory acute myeloid leukemia treated with Mito-FLAG salvage chemotherapy (2021) (1)
Prognostic Factors For Overall Survival In Elderly Patients With Relapsed Acute Myeloid Leukemia – Retrospective Study On Behalf Of The East German Study Group For Hematology and Oncology (OSHO) (2013) (1)
accelerated-phase chronic myelogenous leukemia inhibitor, is active in patients with imatinib-resistant or -intolerant Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase (2008) (1)
Existence and convergence results for periodic Riccati differential equations (1999) (1)
Abstract CT057: Phase 2, open-label, multicenter study to evaluate the efficacy and safety of INCB054828 in patients with myeloid/lymphoid neoplasms with fibroblast growth factor receptor 1 (FGFR1) rearrangement (2017) (1)
Clinical Trials Underestimate Age of Chronic Myeloid Leukemia (CML) Patients: Epidemiological Study in a Representative Area in Germany. (2007) (1)
Publisher Correction: SIRT7: an influence factor in healthy aging and the development of age-dependent myeloid stem-cell disorders (2021) (1)
Assessment Of Early Cytogenetic Response By 3 Months Versus >3-6 Months Or No Response By 6 Months As a Predictor Of Long-Term Clinical Outcomes In a Phase 1/2 Study Of Bosutinib In Chronic Phase CML (2013) (1)
PS1176 PRIMARY RESULTS OF THE PHASE 4 BYOND STUDY OF BOSUTINIB FOR PRETREATED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (2019) (1)
Bosutinib in Newly Diagnosed Chronic Myeloid Leukemia (CML): Gastrointestinal (GI), Liver, and Hematological Safety Characterization in the BFORE Trial (2017) (1)
Quantification of BCR-ABL by digital PCR in samples with high copy numbers and rates of molecular responses (as defined by EUTOS) compared to those detected with standard quantitative real-time PCR. (2016) (1)
Prognostic Factors for Overall Survival in Relapsed Acute Myeloid Leukemia (2014) (1)
Health-Related Quality of Life Impairment in Patients with Chronic Myeloid Leukemia: Results of a German Cross-Sectional Study of Patients Registered in Prospective, Controlled Clinical Trials (2015) (1)
Clinical Development of Asciminib (ABL001): A Randomized Phase 3 Study of Asciminib vs Bosutinib in Patients with Chronic Myeloid Leukemia (CML) (2018) (1)
Low Level BCR-ABL Mutations Below the Detection Limit of Current Standard Screening Techniques Occur Predominantly in the CD34+ Progenitor Cell Compartment in Chronic Phase CML Patients At Diagnosis. A Substudy of the ENEST1st Trial (2012) (1)
ON THE ASYMPTOTIC BEHAVIOR OF THE SOLUTIONS OF PARAMETER-DEPENDENT MATRIX RICCATI DIFFERENTIAL EQUATIONS WITH RESPECT TO THE PARAMETER (2004) (1)
Protein-tyrosine phosphatases modulate therapy response in CML cells (2016) (1)
State of the Art in CML: Update (2021) (1)
ASC4START: A Phase IIIb, Open-Label, Randomized Study of Tolerability and Efficacy of Asciminib Versus Nilotinib in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia in Chronic Phase (2022) (1)
Diagnosis and Monitoring of Residual Disease by Quantitative RT-PCR in Eosinophilia-Associated Myeloproliferative Disorders with Rearrangements of PDGFRA and PDGFRB. (2006) (1)
Distinct Characteristics of e13a2 versus e14a2 BCR-ABL Chronic Myeloid Leukemia under Upfront Treatment with Imatinib – an Analysis of the German CML Study IV, (2011) (1)
PF405 DASCERN 2-YEAR EXTENDED FOLLOW-UP OF DASATINIB EFFICACY AND SAFETY IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) WHO HAVE SUBOPTIMAL RESPONSES TO 3 MONTHS OF IMATINIB (2019) (1)
Prognostic Factors Identified Via a Cox Proportional Hazard Cure Model Explain Survival Differences After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Chronic Myeloid Leukemia (CML) Between Two Consecutive Patient Cohorts (2012) (1)
Leukemianet Recommendations from an expert panel on behalf of the European Evolving concepts in the management of chronic myeloid leukemia. (2011) (1)
Harmonization of Molecular Monitoring of CML Therapy in Europe – Perspective of Widespread Competence in BCR-ABL Quantification. (2009) (1)
Effect of Dose Modifications on 5-Year Efficacy of Dasatinib and Imatinib in Newly Diagnosed Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) From DASISION (2017) (1)
Treatment and Outcome Analysis of 2,904 Pateints from the EUTOS Population Based Registry (2015) (1)
Congress Report: XIX symposium of the International Association for Comparative Research on Leukemia and Related Diseases, Mannheim/Heidelberg, Germany, July 13 - 18, 1997. (1998) (1)
cytochrome P-450 gene polymorphism CYP1A1*2A Reduced risk for chronic myelogenous leukemia in individuals with the (2013) (1)
A phase I study of INNO-406, a dual inhibitor of Abl/Lyn kinases, in adult patients with imatinib-resistant or intolerant Philadelphia chromosome positive (Ph+) leukemias (2007) (1)
Effects of imatinib mesylate in patients with polycythemia vera: results of a phase II study (2013) (1)
MDR1 Gene Expression Predicts Response and Progression-Free Survival Of Ph+ CML Patients On Second-Line Nilotinib Therapy After Imatinib Failure - 4-Year Follow-Up (2013) (1)
BCR-ABL Kinase Domain Mutations and Their Kinetics on Second Line Dasatinib or Nilotinib Therapy in CML Patients after Imatinib Failure: A Cooperative Evaluation of Four Different Detection Methods. (2007) (1)
Mutations in the plasma cell clone identify mechanism of polyneuropathy in a case of POEMS syndrome associated with Castleman disease and multiple myeloma (2022) (1)
Safety and Efficacy of Nilotinib Dose Escalation 600mg BID in Patients (pts) with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP). (2007) (1)
Induction with Bortezomib Melphalan and Prednisolon (VMP) Is Associated with Unexpectedly High Discontinuation Rate in Elderly Multiple Myeloma Patients: First Analysis of the German Maintenance (GERMAIN) Trial (2018) (1)
Defining Therapy Goals for Major Molecular Remission in Chronic Myeloid Leukemia: Results of the Randomized CML-Study IV (2014) (1)
Single-Cell Immune Signatures in Patients with Chronic Phase Chronic Myeloid Leukemia (CML) Treated with Nilotinib: An ENEST1st Sub Study (2015) (1)
Centrosome Aberrations in Chronic Myeloid Leukemia (CML) Are Correlated with Disease Progression and Chromosome Instability. (2004) (1)
Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) with a Related Donor in Chronic Myeloid Leukemia (CML): An Explanation for Fast Improvement of Survival in Two Consecutive German CML Studies. (2009) (1)
Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34 (cid:1) cells (2007) (1)
A Comprehensive Deep-Sequencing Study of Blast Crisis Chronic Myeloid Leukemia (CML) Reveals New Insights Into Molecular Heterogeneity and Detects Mutations In 12 Different Genes In 82.5% of Cases (2010) (1)
Subcutaneous omacetaxine mepesuccinate in chronic myeloid leukemia (CML) patients resistant or intolerant to two or more tyrosine kinase inhibitors (TKIs): Data from an ongoing phase II trial. (2016) (1)
Reply to Inokuchi et al (2006) (1)
Increased LFS Following Hematopoietic Cell Transplantation As Compared to Conventional Consolidation Therapy in Patients >60 Years with AML in First Complete Remission and a Matched Donor: Results of a Randomized Phase III Study (2022) (1)
Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia (2021) (1)
Increasing The Dose Of AraC In Consolidation Therapy Does Not Lead To Higher Overall Survival Or Improved Relapse Incidence In Patients With AML Over The Age Of 60 Years (2013) (1)
Efficacy and Safety of Bosutinib in Previously Treated Patients with Chronic Myeloid Leukemia: Final Results from the Byond Trial (2021) (1)
Characterization of Two New Imatinib-Responsive Fusion Genes Generated by Disruption of PDGFRB in Eosinophilia-Associated Chronic Myeloproliferative Disorders. (2006) (1)
HGNC nomenclature for fusion genes (2021) (1)
Mutation Analysis of BCR-ABL Tyrosine Kinase Domain In New Chronic Phase-Chronic Myeloid Leukemia Patients with Suboptimal Response or Treatment Failure From Imatinib Treatment. (2010) (1)
Clinical development of asciminib (ABL001) in chronic myeloid leukemia (CML): A randomized phase 3 study vs. bosutinib. (2018) (1)
Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique (2003) (1)
Increased TACE (Tumor necrosis factor-alpha±-converting enzyme; ADAM17) Activity Associates with Decreased CD62L Expression, Increased Soluble CD62L Plasma Levels and Predicts Molecular Response to Nilotinib Therapy in Patients with Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP): Results (2015) (1)
Klinische Studien in der Hämatologie und Onkologie (2022) (1)
Detection of new mutations in patients (pts) with imatinib-resistant chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib. (2010) (1)
Ornithine transcarbamylase (OTC) deficiency based on a hemizygous p.R277W mutation causing life-threatening hyperammonemic crisis during treatment for Hodgkin’s lymphoma (2011) (1)
MINI-REVIEW Detection and quantification of residual disease in chronic myelogenous leukemia (2000) (1)
Prävention und Management kardiovaskulärer Erkrankungen mit Nilotinib (2015) (1)
ASC4FIRST: A Phase III Study of Asciminib vs Investigator-Selected Tyrosine Kinase Inhibitor in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) (2022) (1)
Population pharmacokinetic (PK) and exposure-response analysis of nilotinib in newly diagnosed Ph+ chronic myeloid leukemia in chronic phase: Results from ENESTnd. (2010) (1)
A population based registry in chronic myeloid leukemia (CML), a network of registries covering "representative" areas or regions of Europe (l 10 millions people) (2010) (1)
Epidemiological Study on Survival of Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL) Patients with T315I Mutation. Final Analysis (2008) (1)
ENESTfreedom 144‐Week Update: Long‐Term Treatment‐Free Remission (TFR) Following Frontline Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML‐CP): CML‐188 (2018) (1)
Molecular Response with Nilotinib in Patients with Philadelphia Negative (Ph-) Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENEST1st Sub-Analysis (2015) (1)
Interdisziplinäres COVID-Board bei SARS-CoV-2-getriggerter hyperferritinämischer Inflammation (2020) (1)
NILOTINIB SHOWS SUSTAINED BENEFIT COMPARED WITH IMATINIB IN PATIENTS (PTS) WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): ENESTND 4-YEAR FOLLOW-UP (F/U) (2013) (1)
Standardization of Molecular Monitoring for Chronic Myeloid Leukemia: 2021 Update (2021) (1)
Comments on the Hammersmith policy (2003) (1)
Patients with Chronic Phase CML in the IRIS Study Who Receive Imatinib Mesylate (IM) 2nd Line after Prior IFN/Ara-C Have Sustained Complete Cytogenetic and Major Molecular Response Rates Similar to 1st Line IM Patients. (2006) (1)
Band 25, Heft 3, Juni 2002 (2002) (1)
[Clinical research at the European LeukemiaNet]. (2006) (1)
Impact of Variant t(9;22) and Additional Cytogenetic Aberrations at Diagnosis on Prognosis of CML (2010) (1)
Stopping tyrosine kinase inhibitors in a large cohort of European chronic myeloid leukemia (CML) patients: results of the EURO-SKI trial (2016) (1)
Efficacy and safety results from ASCEMBL, a phase 3 study of asciminib versus bosutinib (BOS) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 prior tyrosine kinase inhibitors (TKIs): Week 96 update. (2022) (1)
Long-Term Follow-up of the Efficacy and Safety of Ponatinib in Philadelphia Chromosome-Positive Leukemia Patients with the T315I Mutation (2016) (1)
Loss or Inhibition of Stromal-Derived PlGF Prolongs Survival of Mice with Imatinib-Resistant Bcr-Abl1+ Leukemia. (2020) (1)
Deregulated CD62L expression predicts molecular response to nilotinib therapy in early chronic phase Chronic Myelogenous Leukemia (CML-CP) (2016) (1)
Elderly CML Patients On Early Applied High Dose Imatinib Achieve Molecular Remissions As Fast As Younger Patients In Contrast To Patients On Standard Dose Imatinib: A Subanalysis Of The German CML-Study IV (2013) (1)
Diagnostik der chronischen myeloischen Leukämie - Charakteristisches Blutbild, Knochenmarkaspiration und Zytogenetik (2007) (1)
Oxaliplatin – idealer Kombinationspartner in der antitumoralen Chemotherapie (2003) (1)
Real life experience with ATRA-arsenic trioxide based regimen in acute promyelocytic leukemia - results of the prospective German intergroup Napoleon registry (2016) (1)
Three-Year Update from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib (2022) (1)
[Tailored management of chronic myeloid leukemia]. (2013) (1)
Gezielte Therapie: alte und neue Hoffnungsträger (2013) (1)
Trial in Progress: A Multicenter, Open Label, Randomized, Phase III Study of Asciminib (80 mg Once Daily) Vs Investigator-Selected TKI in Newly Diagnosed Adult Patients with Chronic Myeloid Leukemia in Chronic Phase (2021) (1)
Efficacy of Ropeginterferon Alpha 2b in Inducing Treatment Free Remission in Chronic Myeloid Leukemia - an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group (2022) (1)
A Mosquito Bite with Devastating Complications in an Immunocompromised Patient (2019) (1)
Die Netzwerkzentrale des Kompetenznetzes „Akute und chronische Leukämien“ (2004) (1)
Prognostic Value of Multi-Drug Resistance 1 Gene ( MDR1) Expression in Newly Diagnosed Patients with Chronic Myeloid Leukemia on Nilotinib Treatment- a Subanalysis of the ENEST1st Study (2014) (1)
Therapiemonitoring der chronischen myeloischen Leukämie - Hämatologische, zytogenetische und molekulare Daten konsequent erheben (2007) (1)
Human mucosal-associated invariant T cells respond to Mucorales species in a MR1-dependent manner. (2020) (1)
[Chronic myelogenous leukemia]. (2015) (1)
Treatment-Free Remission (TFR) Among Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Not Initially Eligible for Treatment Discontinuation Due to Unstable Deep Molecular Response (DMR): Enestfreedom and Enestop (2017) (1)
In CML, Marrow Fibrosis Relapses or Emerges in 5 - 6 % of Patients Per Year Independently Indicating Imatinib Failure and Shortened Survival Time of Patients. (2006) (1)
Auf dem Weg zu kurativen Therapien beim multiplen Myelom? Expertenworkshop zu aktuellen Standards und neuen Entwicklungen (2002) (1)
Adult Patients with Hemophagocytic Lymphohistiocytosis (HLH) in Germany: A Retrospective Multicenter Case Study of 29 Patients (2012) (1)
CML-121: Efficacy and Safety of Asciminib in Heavily Pretreated Patients with Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP) with Sensitivity to Tyrosine Kinase Inhibitors (TKIs) (2020) (1)
Caelyx beim metastasierten Mammakarzinom zugelassen: Neue effektive Therapieoption mit besserer Verträglichkeit dank neuer Galenik (2003) (1)
A high-throughput candidate gene mutation screen in lymphoproliferative and myeloproliferative neoplasias. (2009) (1)
Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study (2022) (1)
Equivalence of BCR-ABL Transcript Levels <1% According to the International Scale with Complete Cytogenetic Response in Chronic Phase CML Patients. (2012) (1)
Early molecular response in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with dasatinib (DAS) or imatinib (IM) from DASISION. (2016) (1)
Die Deutsche CML-Allianz: Ein Modell für intersektorale Kommunikation und Kooperation (2015) (1)
chronic phase vs imatinib in patients with newly diagnosed chronic myeloid leukemia (2013) (1)
Safety and Efficacy of a Combination of Imatinib and Pegylated Interferon α2a (Pegasys®) in Newly Diagnosed Patients with Chronic Myelogenous Leukemia - A Phase II Cohort Study. (2007) (1)
Treosulfan, Fludarabine and Cytarabine As Conditioning before Allogeneic Hematopoietic Stem Cell Transplantation (2018) (1)
Letter to the Editor – Brief an die Herausgeber (1996) (1)
Sensitive Detection of FIP1L1-PDGFRA Fusion Transcripts by Real-Time Quantitative RT-PCR (RQ-PCR) Reveals Achievement of Molecular Remission in Chronic Eosinophilic Leukemia Treated with Low-Dose Imatinib Therapy. (2005) (1)
Nilotinib vs. nilotinib plus interferon a induction and nilotinib or interferon a maintenance therapy for newly diagnosed BCR-ABL positive chronic myeloid leukemia patients in chronic phase: interim analysis of the TIGER (CML V) study (2017) (1)
Entstehung, Entwicklung und Erfolge des Kompetenznetzes Akute und Chronische Leukämien (KNL) (2016) (1)
Concept and feasibility of the randomized comparison of imatinib with imatinib combination therapies for chronic myeloid leukemia: The German CML Study IV - Pilot Phase (2005) (1)
Befundinterpretation der molekularen Diagnostik in der Verlaufskontrolle der chronischen myeloischen Leukämie: Empfehlungen einer deutschen Expertengruppe/Interpretation of molecular diagnostics results in routine monitoring for chronic myeloid leukemia: recommendations from a German expert panel (2012) (1)
Maßgeschneiderte Therapie der chronischen myeloischen Leukämie (2013) (1)
Reduced Expression of CD62L Is Associated with Increased ADAM17 Activity and Predicts Molecular Response to Nilotinib Therapy in Patients with Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP) (2014) (1)
High-Resolution Analysis of the Relationship Between Dose and Molecular Response in CP-CML Patients Treated with Ponatinib or Imatinib (2014) (1)
5-Year Updates from the Pivotal Phase 2 Ponatinib PACE Trial: Efficacy, Safety and Landmark Analysis in Heavily Pretreated Patients with Chronic-Phase Chronic Myeloid Leukemia (2017) (1)
BGB324 Represents an Axl and BCR-ABL1 Inhibitor with Activity in the T315I Mutant (2014) (1)
Tyrosine Kinase Inhibitor Treated CML Patients Harboring Philadelphia-Negative Cytogenetically Aberrant Clones Show Molecular Mutations In 31% Of Cases Not Present At Diagnosis: A High-Throughput Amplicon Sequencing Study Of 29 Genes (2013) (1)
EUROPEAN SUB-REGISTRY OF CHRONIC MYELOID LEUKEMIA (CML) PATIENTS (PTS) IN FAILURE AFTER IMATINIB THERAPY (IFP): RATIONALE, STUDY DESIGN AND CURRENT STATUS. A STUDY FROM THE EUROPEAN LEUKEMIANET (ELN) (2010) (1)
3-year follow-up from a randomized phase 3 trial (DASISION) Early response with dasatinib or imatinib in chronic myeloid leukemia: (2014) (1)
About a generalized algebraic Riccati equation (2002) (1)
High age and high frequency of treatment switch in CML patients outside of clinical trials: interim results of the German CML VI trial (2017) (0)
Prevalence and Dynamics of BCR-ABL Independent Gene Mutations in Patients with Chronic Myeloid Leukemia (2016) (0)
CML-089: Retrospective Independent Review of Arterial Occlusive Events (AOEs) in the Ponatinib Phase 2 PACE Trial (NCT01207440) in Patients with Philadelphia Chromosome Positive (Ph+) Leukemia (2020) (0)
diger Hehlmann Chronic myelogenous leukemia : molecular and cellular aspects (0)
Antibiotic prophylaxis in AML: Comparison of ciprofloxacin and cotrimoxazole in 2 cohorts of patients who received AML induction chemotherapy (2013) (0)
Efficacy and Safety of Bosutinib By Charlson Comorbidity Index in Previously Treated Patients with Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study (2019) (0)
[Multicenter prospective controlled study of therapy of chronic myeloid leukemia. Comparison of busulfan, hydroxyurea and interferon alpha (April 1990 status)]. (1991) (0)
Therapy of older persons with acute myeloid leukemia (2015) (0)
CML-110: Predictors of Durable Treatment-Free Remission After Frontline or Second-Line Nilotinib Treatment in Patients with Chronic Phase Chronic Myeloid Leukemia (2020) (0)
Expression of the CTLA-4 ligand CD86 (B7.2) on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in chronic myeloid leukemia (2016) (0)
WHO-Klassifikation 2022 chronischer myeloproliferativer Erkrankungen (2023) (0)
Auswirkungen einer neoadjuvanten Chemotherapie mit S-1 plus Cisplatin bei szirrhösem Magenkarzinom (2015) (0)
Strahlentherapie bei Chemotherapie-refraktärem rezidivierendem Ovarialkarzinom (2015) (0)
Akute Leukämien des Erwachsenen (2015) (0)
Clinical Cancer esearch cer Therapy : Clinical Open-Label , Phase I Study of the Polo-like Kinase-1 bitor , BI 2536 , in Patients with Advanced R d Tumors (2010) (0)
Chronische myeloproliferative Neoplasien (CMPN) (2020) (0)
Synchrones Auftreten eines Endometrium- und Kolonkarzinoms – welche adjuvante Therapie ist die richtige? (2014) (0)
Übersicht – Therapiekonzepte der chronischen myeloischen Leukämie (CML) (2016) (0)
Philadelphia-positive acute lymphoblastic leukemia ( Ph imatinib-based therapy and give rise to relapse in patients with de novo Kinase domain mutations of BCR-ABL frequently precede (2007) (0)
Existenz-, Konvergenz- und Vergleichssätze für verallgemeinerte Riccatische Matrix-Gleichungen (2002) (0)
Erratum zu: Interdisziplinäres COVID-Board bei SARS-CoV-2-getriggerter Hyperferritinämischer Inflammation (2020) (0)
Ziele und Optionen der palliativen Therapie der akuten myeloischen Leukämie (2022) (0)
Eine Gesellschaft der Methusaleme: Herausforderung und Chance? Ist der Fortschritt in der Medizin noch bezahlbar? (2008) (0)
Die megakaryozytäre Myelose — Klinik, Morphologie und Plättchenfunktion (2005) (0)
Therapie der chronischen myeloischen Leukämie bei älteren Patienten (2010) (0)
Reply to V. Pitini et al (2010) (0)
Autorenverzeichnis «Medizinische Onkologie: Neue Medikamente - Hoffnungsträger mit Risiken» (2013) (0)
Zielgerichtete Therapien bei hämatologischen Erkrankungen (2013) (0)
Influenza virus infections in patients with malignancies –– characteristics and outcome of the season 2014/15. A survey conducted by the Infectious Diseases Working Party (AGIHO) of the German Society of Haematology and Medical Oncology (DGHO) (2016) (0)
„Citius – altius – fortius“ (2017) (0)
Perspektivenwechsel: Ein Wirkstoff für mehrere Krebserkrankungen (2017) (0)
Veränderungen der prognostischen und therapeutischen Parameter beim Prostatakarzinom in den letzten 20 Jahren aus epidemiologischer Sicht (2015) (0)
Chronische myeloische Leukämie : Beste Therapieoptionen ermöglichen zunehmend Remissionen (TOPIC 1 · chronische myeloische leukämie) (2009) (0)
Chronische myeloische Leukämie — State of the Art (2016) (0)
Wünsche und Überzeugungen von Krebspatienten im Hinblick auf Beratung zu ganzheitlicher Medizin (2015) (0)
Kombination von Zytostatika mit Strahlentherapie: Radio-Chemo-Therapie (2006) (0)
Modernes Management der chronischen myeloischen Leukämie* (2018) (0)
Akute Leukämien des Erwachsenen (2015) (0)
Paul Ehrlichs „magic bullets“ und die Präzisionsonkologie (2020) (0)
Verbesserungen der gesundheitsbezogenen Lebensqualität durch umfassende Tumorschmerz-Therapie: Eine Pilotstudie mit ambulanten Brustkrebs-Patientinnen unter palliativer Chemotherapie (2015) (0)
Leukemic stem cell quantification in newly diagnosed chronic myeloid leukemia patients predicts response to nilotinib therapy (2016) (0)
Primäre Zentralnervensystemlymphome (PZNSL) (2015) (0)
Erratum zu: Chronische myeloische Leukämie – State of the Art (2017) (0)
Progressionsrisiko nimmt ab (2006) (0)
Medikamentöse Therapie der chronischen myeloischen Leukämie (2002) (0)
Leukämien als Modellerkrankungen für individualisierte Therapien (2012) (0)
Überleben 65- bis 70-jähriger Patienten mit Multiplem Myelom im Zeitalter von neuen Wirkstoffen und autologer Stammzell-Transplantation - Eine multizentrische, retrospektive, kollaborative Studie der Japanese Society of Myeloma und des European Myeloma Network (2015) (0)
Vorspann (1997) (0)
ONKODIN: Onkologie, HÃ¤matologie - Daten und Informationen (2017) (0)
Klinische Forschung im „European LeukemiaNet” (2006) (0)
Aktuelle Pharmakotherapie der chronischen myeloischen Leukämie (2002) (0)
Editorial (2020) (0)
Phase-II-Studie zu einer Kombinationschemotherapie mit oralem S-1 und Irinotecan als 24-Stunden-Infusion plus Bevacizumab bei metastasierendem Kolorektalkarzinom (2015) (0)
Gynäkologische Tumoren (2020) (0)
Neue Entwicklungen der Systemtherapie maligner Erkrankungen (2019) (0)
Deutsche, Österreichische und Schweizerische Gesellschaften für Hämatologie und Medizinische Onkologie: Gemeinsame Jahrestagung, Leipzig, Oktober 2016: Abstracts (2016) (0)
Myeloproliferative Neoplasien – eine heterogene Entität mit vielen Ähnlichkeiten (2023) (0)
Empfehlungen zur Verlaufskontrolle und Zweitlinientherapie bei der chronischen myeloischen Leukämie (CML) (2010) (0)
Gastrointestinale Tumoren: Irinotecan erhöht die Chance, länger und besser zu überleben. Ergebnisse aus aktuellen klinischen Prüfungen. Clinical Investigators Update Meeting on Gastro-Intestinal Cancer, Sardinien, 20. April 2002 (2002) (0)
Multimodale Therapie von Hypophysenadenomen (2015) (0)
Chronische myeloische Leukämie (2023) (0)
Adjuvante Therapie des kolorektalen Karzinoms (2004) (0)
Paraneoplastische Gerinnungsstörungen (2016) (0)
Kapitel 10 – Chronische myeloproliferative Neoplasien (CMPN) (2012) (0)
Vergleich der Wirksamkeit von Gefitinib bei Patienten mit nichtkleinzelligem Lungenkarzinom nach Art der Mutation des epidermalen Wachstumsfaktor-Rezeptors (2015) (0)
Fortschritte in der Diagnostik und Therapie chronischer Leukämien und Myelodysplasien (2019) (0)
Selektion älterer Patienten mit akuter myeloischer Leukämie für eine intensive Chemotherapie: Wirksamkeit der intensiven Chemotherapie und Subgruppenanalyse (2015) (0)
Achievement Of a MR5.0 Within the Randomized CML-Study IV: Feasibility, Differences Between Treatment Arms, and Prognostic Implications (2013) (0)
10 – Chronische myeloproliferative Neoplasien (CMPN) (2015) (0)
Deutsche Gesellschaft für Hämatologie und Onkologie e.V. (2009) (0)
Hmatologie im Spiegel der Zeit: Innovative Substanzen gewinnen mit einem bewhrten Partner Jubilums-Symposium "50 Jahre Bendamustin", Jena, September 2012 (2013) (0)
Chronische myeloproliferative Erkrankungen (2003) (0)
Beratungsbedarf von Heranwachsenden und jungen Erwachsenen nach hämatopoetischer Stammzelltransplantation (2018) (0)
A certi ﬁ ed plasmid reference material for the standardisation of BCR – ABL1 mRNA quanti ﬁ cation by real-time quantitative PCR (2015) (0)
Nicole Muller-Bérat Killmann 1932–2014 Leukemia pioneer (2014) (0)
Die chronische myeloische Leukämie (CML) im Alter (2002) (0)
Interdisziplinarität am Beispiel gastrointestinaler Tumoren (2009) (0)
Correction: Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee (2022) (0)
PF414 DNA-BASED BCR-ABL1 ANALYSIS PROVIDES A “TRAFFIC LIGHT” STRATIFICATION MODEL FOR CHRONIC MYELOID LEUKEMIA WITH IMPLICATIONS FOR TREATMENT FREE REMISSION (2019) (0)
myeloid leukemia Drug treatment is superior to allografting as first-line therapy in chronic (2013) (0)
Erratum (1919) (0)
Modulation of the Radiation Response in U343 Glioblastoma Cells by the Tyrosine Kinase Inhibitor Imatinib Mesylate (2005) (0)
Treatment and outcome of 2904 CML patients from the EUTOSpopulation-based registry (2017) (0)
Multiple analyses affirm the independent adverse influence of ABL/BCR breakpoint spanning deletions on surival in chronic myeloid leukemia (2007) (0)
mutations and for expressing results transcripts and kinase domain BCR-ABL methodology for detecting inhibitors - Review and recommendations for 'harmonizing' current Monitoring CML patients responding to treatment with tyrosine kinase (2011) (0)
Tandem Duplications of the UBTF gene in Adult AML: A Rare but Recurrent Alteration Associated with Myelodysplasia and Poor Outcome (2022) (0)
Immune Monitoring In Patients With Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated With Frontline Nilotinib (2013) (0)
XIX Symposium of the International Association for Comparative Research on Leukemia and Related Diseases (1998) (0)
Impact of Landmark Responses on 3-Year Outcomes in CP-CML Patients in the Ponatinib PACE Trial (2016) (0)
Revealing the true face behind the mask of ALK-positive anaplastic large cell lymphoma (ALCL) (2020) (0)
To the Editor. ABL-BCR expression does not correlate with deletions on the derivative chromosome 9 or survival in chronic myeloid leukemia (2001) (0)
Efficacy and Safety Outcomes by Baseline Comorbidity and Age in Patients Newly Diagnosed with Chronic Myeloid Leukemia in Chronic Phase (CML‐CP) and Treated with Dasatinib or Imatinib in DASISION: Abstract: CML‐005 (2017) (0)
Clinical and laboratory findings in adult patients with Hemophagocytic Lymphohistiocytosis: Update from the German aHLH registry (2016) (0)
EPIC: A Phase 3 Trial of Ponatinib Compared With Imatinib in CP-CML Patients (2015) (0)
Front & Back Matter (2022) (0)
Elevated blood pressure (BP) and adverse events (AEs) of hypertension (HTN) in ponatinib (PON) leukemia trials. (2015) (0)
Maintenance of Health-Related Quality of Life in the Phase 4 BYOND Study of Bosutinib for Pretreated Chronic Phase Chronic Myeloid Leukemia (2019) (0)
Lineage-Specific Metabolic Reprogramming Reveals LKB1 as Therapeutic Target in Acute Lymphoblastic Leukemia (2014) (0)
The Megakaryocytic Myeloid Leukemia: Clinical, Morphological and Functional Aspects (1993) (0)
Case report: Ectopic Cushing syndrome as paraneoplastic manifestation of an advanced small cell lung cancer (2020) (0)
Aggressive Systemic Mastocytosis Is Associated with a High Kit D816V Allele Burden in Peripheral Blood. (2009) (0)
Combination Treatment with Imatinib and Mitoxantrone/Etoposide Is a Suitable Preparative Regimen before Allogeneic Transplantation in Patients with Myeloid Blast Crisis of Chronic Myeloid Leukemia. (2005) (0)
Serial Analysis of BCR-ABL Kinase Domain Mutations Prior to and During Imatinib Treatment for Newly Diagnosed and Recurrent BCR-ABL Positive Acute Lymphoblastic Leukemia. (2009) (0)
Clonal haematopoiesis of indeterminate potential‐related mutations and outcome in dilated and ischaemic cardiomyopathy (2022) (0)
Monitoring of PML-RAR alpha in Patients with Acute Promyelocytic Leukemia (APL) by RT-PCR (1998) (0)
CML-129: OPTIC Primary Analysis: A Dose-Optimization Study of 3 Starting Doses of Ponatinib (PON) (2021) (0)
CML Study IV of CML: long-term observation of 1151 patients from the randomized Impact of additional cytogenetic aberrations at diagnosis on prognosis (2012) (0)
Interferon-α in the Treatment of CML: Comparison of Busulfan versus Hydroxyurea versus Interferon-α (1994) (0)
CML-413: Asciminib Provides Durable Responses and a Favorable Safety Profile in Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) with the T315I Mutation in a Phase 1 Study (2021) (0)
The small molecule axl inhibitor BGB324 shows activity against T315I-mutated and BCR-ABL1 wt chronic myeloid leukemia (2014) (0)
Essential Thrombocythemia: Current Opinion in Diagnosis, Clinical Course, and Treatment (1996) (0)
Response: Drug treatment and allografting as first-line therapy in young patients with CML (2007) (0)
Acknowledgement to Reviewers (2016) (0)
Mathematical Modelling Of The Molecular BCR-ABL1 Transcript Response In Chronic Myeloid Leukemia: A Comparison Of Adult and Pediatric Patients (2013) (0)
The JAK1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation (2020) (0)
Erkrankungen des Blutes (2003) (0)
Treatment-Free Remission (TFR) Following Frontline or Second-Line Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTfreedom and ENESTop (2016) (0)
Prof. Michele Baccarani, August 16, 1942 to December 20, 2021: a gifted life in haematology (2022) (0)
Characterization of Three New Fusion Genes Generated by Disruption of PDGFRB in Eosinophilia-Associated Chronic Myeloproliferative Neoplasms (2008) (0)
Frequency and Clinical Presentation of Polycomb Repressive Complex 2 (PRC2) Component Mutations in Childhood Acute Lymphoblastic Leukemia (2012) (0)
CML with E8A2 BCR-ABL Fusion: The Fourth Breakpoint Cluster Region?. (2004) (0)
Treatment and Disease Characteristics of Chronic Myeloid Leukemia in Blast Crisis: The European Leukemianet Blast Crisis Registry (2022) (0)
Weißes Blut (2022) (0)
Bone Marrow (BM) Microenviroment Factors As Early Markers of Response in Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated with Nilotinib (2015) (0)
positive chronic eosinophilic leukemia - FIP1L1-PDGFRA responses and achievement of complete molecular remission in Low-dose imatinib mesylate leads to rapid induction of major molecular (2013) (0)
Pomalidomide plus ruxolitinib in myelofibrosis: Updated results from the MPNSG-0212 trial (2017) (0)
Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome (2023) (0)
FIP1L1-PDGFRA Positive Secondary Acute Myeloid Leukemia. (2005) (0)
BGB324 Inhibits BCR-ABL TKI-Resistant Chronic Myeloid Leukemia (2015) (0)
Dmg treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Commentary (2007) (0)
CML Patients' Views on Psychological Support throughout the Treatment-Free Remission Journey (2019) (0)
Dual targeting of tyrosine kinase and BCL6 signaling for leukemia stem cell eradication (2018) (0)
Full Dose or Reduced Dose Melphalan (MEL) for Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM): A Single Center Analysis on 187 Consecutive Patients (2018) (0)
Critical Evaluation of Diverse Clinical, Laboratory, Radiological and Histological Parameters Indicating Gastrointestinal Involvement for Diagnosis of Indolent and Aggressive Systemic Mastocytosis (2011) (0)
The predictive impact of MDR1 expression and pre-tumor burden on molecular, cytogenetic and clinical outcome of CML patients on nilotinib therapy after imatinib failure (2010) (0)
Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial (2022) (0)
Pregnancy and spontaneous delivery in a patient with primary myelofibrosis (2012) (0)
Measuring Phagocytosis of Aspergillus fumigatus Conidia by Human Leukocytes using Flow Cytometry. (2019) (0)
Complete or Partial Deletions of IKZF1 Occur In 28% of Blast Crisis CML and Are the Only Recurrent Submicroscopic Alteration Associated with Disease Progression: An Analysis of 43 Cases Using High-Resolution Genome-Wide Copy Number DNA Arrays and Molecular Assays (2010) (0)
Model-based prediction of patient-specific residual disease levels for imatinib-treated chronic myeloid leukemia. (2011) (0)
The ATP Competitor INNO-406 (NS-187) Inhibits Proliferation and Survival of Mouse Cells Expressing Several Immatinib Mesylate Resistant Bcr/Abl Mutants and Cells from CML Patients. (2006) (0)
TKI dis con tin u a tion in CML : how do we make more patients eli gi ble ? How do we increase the chances of a suc cess ful treat ment-free remis sion ? (2021) (0)
Discontinued at Least 90 Days Before the Procedure Myelogenous Leukemia Does Not Affect Outcome Adversely, Provided It Is Interferon-? Before Allogeneic Bone Marrow Transplantation in Chronic (2013) (0)
No more transplantation in CML? Authors' reply (2007) (0)
Adolescent and young adults versus older adults in the setting of allogeneic stem cell transplantation - two cohorts with special needs (2016) (0)
Molecular Recurrence-Free Survival (MRecFS) Following Imatinib Vs. Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Matched Analysis of Patients in EURO-SKI and Enestfreedom (2017) (0)
progenitors genomic instability in chronic myeloid leukemia stem cells and primitive mitochondrial respiratory chain complex III-generated ROS cause - Rac2 (2012) (0)
Predicting Early Relapse for Patients with Multiple Myeloma through Machine Learning (2021) (0)
Real World Data on Decitabine Treatment in 296 Patients with Acute Myeloid Leukemia: Outcome and Impact of TP53 Mutations (2017) (0)
Clara Bloomfield MD: Queen of AML. Dare to cross her at your risk (May 15, 1942 to March 1, 2020) (2020) (0)
Breast cancer: precancerous lesions (2006) (0)
Exceptional response to neoadjuvant targeted therapy with the selective RET inhibitor selpercatinib in RET-fusion-associated sarcoma. (2022) (0)
Molecular characterization of EZH 2-mutant patients with 2 myelodysplastic / myeloproliferative neoplasms 3 (2017) (0)
P-164 Paraneoplastic inflammatory disease in myelodysplastic syndrome or bone marrow failure: A clinical case series (2013) (0)
PTEN Is Essential for Normal Cytokine Signaling and Oncogenic Transformation of Pre-B Cells (2014) (0)
Leukemic Stem Cell Quantification Is Of Prognostic Value In Newly Diagnosed Patients In Chronic Phase Chronic Myeloid Leukemia (CML-CP) Receiving Nilotinib Therapy: Results From The ENEST1st Stem Cell Substudy (2013) (0)
Response and outcomes to nilotinib at 24 months in patients with imatinib-resistant chronic myeloid leukemia in chronic phase and accelerated phase with and without BCR-ABL mutations (2010) (0)
Single Versus Double Induction with "7+3" Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial (2022) (0)
P719: EFFICACY AND SAFETY OF BOSUTINIB IN LATER-LINE PATIENTS WITH CHRONIC MYELOID LEUKEMIA: A SUB-ANALYSIS FROM THE PHASE 4 BYOND TRIAL (2022) (0)
MYELOID NEOPLASIA Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (2013) (0)
Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis. (2023) (0)
Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation (2022) (0)
No evidence for a major role of nibrin gene exon 6 aberrations in the pathogenesis of hematological malignancies (2000) (0)
Efficacy and safety of imatinib in CML over 10 years. (2014) (0)
INACTIVATING MUTATIONS OF THE HISTONE METHYLTRANSFERASE EZH2 ARE ASSOCIATED WITH CHROMOSOME 7 ABNORMALITIES IN MYELOID DISORDERS (2010) (0)
Imatinib (STI571) for the Treatment of Chronic Myelogenous Leukemia (CML) (2003) (0)
Quantitative Assessment of the Impact of Interferon Alpha (IFN) vs. Busulfan vs. Hydroxyurea and of Risk Profile on Survival in Chronic Myelogenous Leukemia (CML) (1998) (0)
Ten-year survival after randomized comparison of imatinib (IM) 400 mg vs. IM 800 mg vs. IM + IFN vs. IM + Ara C vs. IM after IFN in chronic myeloid leukemia (CML). (2017) (0)
Treatment with Tyrosine Kinase Inhibitors (2007) (0)
Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group (2022) (0)
The Cytogenetic Profile In Lymphoid and Myeloid CML Blast Crisis (2013) (0)
Bcr-Abl mutations in imatinib-resistant CML and Ph+ALL patients (pts) enrolled in a phase I study of AMN107. (2006) (0)
OP-05 Detection and characterization of circulating epithelial tumor cells in liver cancer patients (2013) (0)
PB2158 POMALIDOMIDE, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (PCD) IS AN EFFECTIVE SALVAGE REGIMEN FOR MULTIPLE MYELOMA (MM) PATIENTS RELAPSED ON OR REFRACTORY TO DARATUMUMAB (2019) (0)
Ultra-precise quantification of mRNA targets across a broad dynamic range with nanoreactor beads (2020) (0)
Chronic Myeloid Leukemia (CML): A Model Disease for Utilizing Evidence Based Guidelines in a Decade of Progress. (2006) (0)
responders : a study of complete cytogenetic α Chronic myeloid leukemia and interferon- (2013) (0)
Model-based prediction of residual leukemic stem cell dynamics in tyrosine kinase inhibitor-treated chronic myeloid leukemia (CML) (2013) (0)
Outcomes in Patients with Chronic Myeloid Leukemia in the Chronic Phase Randomized to Dasatinib or Imatinib after Suboptimal Responses to 3 Months of Imatinib Therapy: Final 5-Year Results from DASCERN (2022) (0)
Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results. (2023) (0)
Therapy of Newly Diagnosed and Chronic‐Phase Chronic Myeloid Leukemia (2011) (0)
Ruxolitinib Versus Best Available Therapy in Patients with Essential Thrombocythemia: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN) (2022) (0)
Outcomes after allogeneic haematopoietic stem cell transplantation in young adults in Germany (2022) (0)
Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia (2013) (0)
Indoleamine 2,3-Dioxygenase (Ido1) activity is increased in early chronic phase Chronic Myelogenous Leukemia (CML) and predicts molecular response to nilotinib therapy (2017) (0)
Clinical Phenotype of Myeloproliferative Neoplasms with Activating CBL-mutations Resembles Chronic Myelomonocytic Leukemia. (2009) (0)
Incidence, Risk Factors, Treatment and Long Term Outcome of Refractory and First Relapse AML Patients in the OSHO Studies (2019) (0)
Major Route Additional Chromosomal Aberrations (ACA) Precede Increase of Blasts in CML: An Analysis of the German CML-Studies III and IIIA (2015) (0)
The Impact Of Balanced and Unbalanced Karyotypes On Prognosis Of CML: From Chronic Phase To Blast Crisis (2013) (0)
PROSPECTIVE MULTICENTER STUDY FOR TREATMENT OF CHRONIC MYELOCYTIC-LEUKEMIA - COMPARISON OF BUSULFAN, HYDROCYUREA AND INTERFERON ALPHA (UPDATE APRIL, 1990) (1991) (0)
Impact of treatment intensity on infectious complications in patients with acute myeloid leukemia (2022) (0)
Comparison of survival between patients with and without switch to second-line tyrosine kinase inhibitor in a trial on chronic myeloid leukaemia with randomisation to first-line imatinib (2016) (0)
Psychosocial distress in young adults surviving hematological malignancies: a pilot study. (2022) (0)
Genomic anatomy of the t(15;17): Significant subclustering of genomic breakpoints within RAR alpha intron 2. (2001) (0)
[Chronic myeloid leukemia]. (2011) (0)
myeloid leukemia in chronic phase treated with frontline nilotinib or Early molecular response predicts outcomes in patients with chronic (2014) (0)
Impact of emerging ACA on survival in chronic myeloid leukemia (CML) (2022) (0)
Absolute BCR-ABL Transcript Levels At 3 Months but Not At Diagnosis Predict Survival of Chronic Myeloid Leukemia (CML) Patients On Imatinib Therapy (2012) (0)
Oral Abstract: CML-129: OPTIC Primary Analysis: A Dose-Optimization Study of 3 Starting Doses of Ponatinib (PON) (2021) (0)
Correction: The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AML (2020) (0)
HERV expression profiling in acute and chronic myeloid leukemia by means of a retrovirus-specific microarray (2007) (0)
Abstract 3297: CD90/Thy-1-positive cells in the peripheral blood of tumor patients co-express CD44 (2010) (0)
Drug treatment or stem cell transplantation as primary treatment for patients with CML (2007) (0)
B-Lymphoid Transcription Factors Restrict Glycolytic Energy Supply for Oncogenic Signaling (2015) (0)
Interferon- (cid:1) , but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a speciﬁc T-cell response in chronic myeloid leukemia (2002) (0)
Correction to: Knowledge transfer as a tool towards improvement of cancer care in low- and middle-income countries. 6th European Roundtable Meeting (ERTM), June 14th, 2019, Berlin, Germany (2021) (0)
Complete hematologic response to sunitinib in an eosinophilia-associated chronic myeloproliferative disorder with an ETV6-FLT3 fusion gene (2007) (0)
ASXL1 Mutations Predict Inferior Molecular Response to Nilotinib Treatment in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase (2022) (0)
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry. (2022) (0)
Minimal residual disease in chronic myelogenous leukemia: results of RT-PCR detection of BCR-ABL transcripts (2003) (0)
Prof. Michele Baccarani. August 16, 1942 to December 20, 2021: a gifted life in haematology (2022) (0)
Molecular-defined clonal evolution in patients with classical myeloproliferative neoplasms. (2023) (0)
Health-related quality of life of patients with resistant/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial. (2023) (0)
[Current pharmacotherapy of chronic myeloid leukemia]. (2002) (0)
A Two-Fold Rise of BCR-ABL Transcript Levels Advises BCR-ABL Mutation Analysis in Imatinib-Treated Chronic Myeloid Leukemia (CML) - an Analysis of the Randomized CML-Study IV (2014) (0)
antagonizes BCR/ABL and down-regulates bcl-2 Interferon Consensus Sequence Binding Protein (ICSBP, IRF-8) (2013) (0)
LeukemiaNet: A transnational model for cooperative leukemia research. (2011) (0)
Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms (2020) (0)
Mutants de domaines de la kinase de l'ABL (2002) (0)
Impact of landmark responses on 3-year (yr) outcomes with ponatinib in heavily pretreated CP-CML patients (pts). (2016) (0)
Acknowledgement to Reviewers (2011) (0)
Development and evaluation of a secondary reference panel for BCR-ABL1 quantitation on the International Scale OPEN (2016) (0)
Nilotinib appears beneficial in Phase I study for patients with Gleevec-resistant CML (2006) (0)
Mutant of the kinase domain of ABL (2002) (0)
CML-046 Dose Modification Dynamics of Ponatinib in Patients With Chronic-Phase Chronic Myeloid Leukemia From the PACE and OPTIC Trials. (2022) (0)
Telomere Shortening At Diagnosis Of Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Is Significantly More Pronounced In Patients With Less-Than-Optimal Versus Optimal Molecular Response (ELN criteria) After 12 Months Of Treatment With Nilotinib (2013) (0)
Analysis of Philadelphia Negative Clones Detected during Treatment with Tyrosine Kinase Inhibitors: A Study on 63 CML Cases. (2007) (0)
The 3-month velocity of BCR-ABL decline: a tool for predicting deep molecular response in CML patients (2016) (0)
Response to the Comments from the Groupe Francophone de Cytogénétique Hématologique (GFCH) on the 5th edition of the World Health Organization classification of haematolymphoid tumors. (2023) (0)
Paraneoplastische Gerinnungsstörungen (2013) (0)
Sensitive Detection of c-kit Point Mutations by D-HPLC in Peripheral Blood and Bone Marrow Samples from Patients with Systemic Mastocytosis. (2006) (0)
Isolation of Hafnia paralvei co-harbouring blaNDM-1 and blaVIM-1 in a woman who underwent allogeneic hematopoietic stem cell transplantation (2023) (0)
Treatment free remission in CML patients after first line nilotinib therapy (2016) (0)
Imatinib Treatment Induces Growth and Survival Promoting MAPK1/2 in Hematopoietic Cell Lines Expressing BCR-ABLT315I. (2007) (0)
Molecular Characterization Of Myelofibrosis Patients With Cytopenia Treated With Pomalidomide: Results From The Mpnsg 01-09 Study (2013) (0)
[Leukemia research in Germany: the Competence Network Acute and Chronic Leukemias]. (2016) (0)
BOSUTINIB VS IMATINIB FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA: INITIAL RESULTS FROM THE BFORE TRIAL (2017) (0)
A standardized in vitro blood-brain barrier model for studying nanocarrier transport at biological barriers (2016) (0)
ASC4OPT: A Phase 3b Open-Label Optimization Study of Oral Asciminib in Chronic Myelogenous Leukemia in Chronic Phase Previously Treated with 2 or More Tyrosine Kinase Inhibitors (2022) (0)
[Megakaryocytic myelosis--clinical aspects, morphology and platelet function]. (1989) (0)
CML-277: Efficacy of Bosutinib in Imatinib-Resistant vs Dasatinib/Nilotinib-Resistant Chronic Phase Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study (2020) (0)
Acknowledgement to Reviewers (2018) (0)
Impact of the Indoleamine 2,3-dioxygenase (IDO) system and its metabolites on molecular response to Nilotinib therapy in early Chronic Phase Chronic Myelogenous Leukemia (CML-CP) (2016) (0)
Metabolic gatekeeper function of B-lymphoid transcription factors (2017) (0)
Step-in Dosing in the Bosutinib Dose Optimization Study (BODO) Failed to Reduce Gastrointestinal (GI) Toxicity in Patients Failing Second Generation TKI (2G-TKI) in Chronic Phase Chronic Myeloid Leukemia (CML) but Suggests Promising Molecular Response (2021) (0)
Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase (2011) (0)
Monitoring of Phosphorylated CRKL in Imatinib Resistant Patients with BCR-ABL Positive Leukemias Expressing BCR-ABL Mutants Treated with AMN107. (2005) (0)
Different clones of acute leukemia after successful treatment of Hodgkin’s disease (2014) (0)
CML-423 Trial in Progress: A Phase III Study of Asciminib vs an Investigator-Selected Tyrosine Kinase Inhibitor (TKI) in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP). (2022) (0)
First-in-Human Study of Elvn-001, a Highly Selective BCR::ABL1 Tyrosine Kinase Inhibitor, in Patients with Chronic Myeloid Leukemia Who Failed Previous Tyrosine Kinase Inhibitor Therapies (2022) (0)
Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy (2022) (0)
Treatment of elderly CML patients with imatinib - final report of the observational study ElderGli with respect to safety and efficacy in clinical practice (2011) (0)
Correction to: Allogeneic hematopoietic stem cell transplantation improves long‑term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials (2021) (0)
Correction to: An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase (2017) (0)
Second-Line Ponatinib in Chronic Phase Chronic Myeloid Leukemia (CML-CP) Patients Failing or Intolerant to First-Line Second Generation Tyrosine Kinase Inhibitor (TKI) Treatment: An Interim Analysis of the Prospective PONS Trial (2022) (0)
[Hereditary elliptocytosis with detection of a membrane protein defect of erythrocytes]. (1988) (0)
KIT D816V and JAK2 V617F Point Mutations Are Recurrently Found In Suspected Hypereosinophilic Syndrome (2010) (0)
PD-0021 Hand-Foot-Syndrome (HFS) is a Clinical Predictor of Survival in Capecitabine Treated Patients (PTS) with Colorectal Cancer (2012) (0)
Importance of and Satisfaction with Information about Their Disease in Cancer Patients (2019) (0)
Hematologic Malignancies-Leukemia , Myelodysplastic Syndromes , & Allotransplant (2016) (0)
Association of Interphase Fluorescence in Situ Hybridization (IP-FISH) Response Criteria with Conventional Metaphase Cytogenetics in CML Patients On Therapy. (2009) (0)
Impact of unbalanced karyotypes at diagnosis on prognosis of CML. (2015) (0)
A 19-year-old patient with atypical chronic myeloid leukemia (2020) (0)
The KIT D816V Allele Burden in Systemic Mastocytosis Is Strongly Associated with Disease Subtype. (2012) (0)
Bosutinib in patients with chronic phase chronic myeloid leukemia intolerant to prior tyrosine kinase inhibitors: Analyses from the BYOND study. (2020) (0)
Title Pages / Table of Contents (2012) (0)
The Pattern Of Cytogenetic Aberrations In CML BC Stratified For Treatment (2013) (0)
Minimal Residual Disease in Chronic Myelogenous Leukemia (2003) (0)
Outcome of Patients with Chronic Myeloid Leukemia After Allogeneic Stem Cell Transplantation in Europe; Data From the EUTOS for CML Registry (2011) (0)
KAPITEL 10 – Chronische myeloproliferative Erkrankungen (CMPE) (2006) (0)
Molecular predictors for the response to nilotinib treatment after acquired imatinib failure in ph+ chronic myeloid leukemia (2010) (0)
study : Presented in part at the 43rd Annual Meeting of The American chronic myelogenous leukemia in myeloid blast crisis: results of a phase II Imatinib induces hematologic and cytogenetic responses in patients with (2013) (0)
A Multicenter Phase I/II Trial of the Combination of Imatinib Mesylate with Mitoxantrone/Etoposide and Cytarabine in Patients with CML in Myeloid Blast Crisis: A Trend to a Longer Survival in Patients Receiving More Aggressive Treatment Schedules. (2004) (0)
MSR19 A Matching-Adjusted Indirect Comparison of Asciminib Versus Ponatinib, Nilotinib and Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients after ≥2 Tyrosine Kinase Inhibitors (2022) (0)
Association Between EZH2 and Other Acquired Mutations In Myelofibrosis and Myelodysplastic/Myeloproliferative Neoplasms (2010) (0)
BCR-ABL transcript analysis of patients (pts) with imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib. (2010) (0)
High-Resolution Analysis of the Relationship Between Ponatinib Dose and Molecular Response in CP-CML Patients in the PACE Trial (2015) (0)
Five-Year Efficacy and Safety of Dasatinib and Imatinib by Baseline Comorbidity and Age in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) from DASISION (2017) (0)
Cancer Immunotherapy (2020) (0)
CD62L Expression on T Cells is Decreased in Patients with Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP) and Predicts Response to Therapy with Frontline Nilotinib (2014) (0)
Characterization of two new fusion genes in the 8p11 myeloproliferative syndrome (EMS) generated by disruption of FGFR (2003) (0)
CML-395 Efficacy and Safety Results From ASCEMBL, a Phase III Study of Asciminib vs. Bosutinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): Week 96 Update. (2022) (0)
Histomorphological and Cytogenetic Investigations in Chronic Myeloproliferative Diseases (1993) (0)
Bosutinib vs imatinib for newly diagnosed chronic myeloid leukemia (BFORE trial) : 24-month efficacy update and results by 3-month BCR-ABL1 transcript levels (2018) (0)
Knowledge transfer as a tool towards improvement of cancer care in low- and middle-income countries. 6th European Roundtable Meeting (ERTM), June 14th, 2019, Berlin, Germany (2020) (0)
Proposal for an efficient schedule for genetic diagnostics in chronic myeloid leukemia (2000) (0)
Abstract LB-36: Circulating epithelial tumor cells are responsive to BMP-2 (2011) (0)
Immune Checkpoint Blockade (2021) (0)
Modeling BCR-ABL Transcript Dynamics in CML Patients under Imatinib Treatment. (2006) (0)
Mechanisms underlying loss of reciprocal fusion gene expression in acute promyelocytic leukaemia: evidence for deletions on der(17) and complex rearrangements yielding novel fusion gene transcripts (2003) (0)
Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors. (2023) (0)
P-212: Quantifying the average treatment effect of single vs. tandem autologous stem cell transplantation in newly diagnosed multiple myeloma using causal inference (2022) (0)
Genomic Landscape and Molecular Risk in Patients with Advanced Myelofibrosis Treated within the Multicenter Phase Ib/II MPNSG0212 (POMINC) Trial (2021) (0)
Efficacy and safety of bosutinib in later-line patients (pts) with chronic myeloid leukemia (CML): A sub-analysis from the phase 4 BYOND trial. (2022) (0)
myeloid leukemia expression of myeloblastin and a specific T-cell response in chronic , but not the ABL-kinase inhibitor imatinib (STI571), induces α Interferon (2013) (0)
Efficacy and Safety of Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor Targeting the Myristoyl-Binding Site, in Patients with Chronic Myeloid Leukemia (CML) Carrying the T315I Mutation (2019) (0)
Low Level BCR-ABL Mutations and Response to Treatment: A Substudy of the ENEST1st Trial (2014) (0)
[Targeted therapy: old and new possibilities]. (2013) (0)
Detection of Enterococcus spp. in bronchoalveolar lavage fluid of patients with high-risk neutropenia: May it be ignored? (2016) (0)
[Aggregative behavior and calcium content of platelets in thrombocythemia and thrombocytosis]. (1990) (0)
Long Term Follow up of the AML97-Study for Patients with AML Older Than 60 Years: A Study of the East German Hematology and Oncology Study Group (OSHO) (2014) (0)
Dynamics of Response and Response Factors in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase 3 Ascembl Study (2022) (0)
Pomalidomide combinations are a safe and effective option after daratumumab failure. (2023) (0)
chronic-phase chronic myeloid leukemia after failure of imatinib therapy Dasatinib induces notable hematologic and cytogenetic responses in (2013) (0)
Mutational Complexity Is Related To Disease Severity In Systemic Mastocytosis (2013) (0)
Treatment-Free Remission (TFR) Following Frontline Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 192-Weeks Data from the ENESTfreedom Study (2019) (0)
An international study to standardize the detection of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCR (2003) (0)
Iron Deficiency Status in Polycythemia Vera Correlates Well with Bone Marrow Angiogenesis in Patients Treated with Phlebotomy. (2004) (0)
Therapy in Patients with Chronic Myeloid Leukemia Outside of Clinical Trials: Results of the German CML-Registry (CML-VI) (2022) (0)
Anti-CD20–atezolizumab–polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma (2022) (0)
Elihu H. Estey, MD: leukemia expert, statistician, and gentle soul (July 15, 1946–October 8, 2021) (2021) (0)
Effect of simultaneous or sequential treatment with Imatinib mesylate on the radiosensitivity of U343MG glioblastoma cells in vitro. (2006) (0)
Analysis of Chromosomal Translocations (2005) (0)
Chronische myeloproliferative Erkrankungen. Diagnostik und Therapie (2003) (0)
PB1902: ASC4OPT TRIAL IN PROGRESS: A PHASE 3B OPEN-LABEL OPTIMIZATION STUDY OF ORAL ASCIMINIB IN CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE PREVIOUSLY TREATED WITH 2 OR MORE TYROSINE KINASE INHIBITORS (2022) (0)
Taxane plus Trastuzumab im Vergleich zu oralem Vinorelbin plus Trastuzumab bei metastasierendem Brustkrebs mit HER2-Überexpression (2015) (0)
[Drug therapy of chronic myeloid leukemia]. (2002) (0)
P1055: CLINICAL AND GENETIC RESULTS OF THE PHASE IB/II TRIAL MPNSG-0212: RUXOLITINIB PLUS POMALIDOMIDE IN MYELOFIBROSIS WITH ANEMIA (2022) (0)
The European Treatment and Outcome Study (EUTOS) for Chronic Myeloid Leukemia (CML). A Prospective, Population-Based European Registry. (2009) (0)
Standardisation of molecular monitoring for CML in Germany using a cell-based BCR-ABL1 secondary reference panel (LYO panel) (2018) (0)
Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study (2023) (0)
MDR1 Expression and Pre-Treatment Tumor Load Predict Molecular Response in CML Patients On Nilotinib Therapy After Imatinib Failure. (2009) (0)
Abstract 1124: Transcriptional control of B cell identity restricts metabolic fitness in human leukemia (2015) (0)
Outcome of CML patients with ABL tyrosine kinase mutations after hematological resistance to imatinib (2004) (0)
Indoleamine 2,3-Dioxygenase (IDO1) Levels and Activity Are Increased in Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP) and Correlate with Molecular Response to Nilotinib Therapy (2016) (0)
Clara Bloomfield MD: Queen of AML. Dare to cross her at your risk (May 15, 1942 to March 1, 2020) (2020) (0)
Effect of cytogenetics at diagnosis on outcome of CML: Results from the randomized German CML Study IV. (2011) (0)
Bosutinib (BOS) vs Imatinib (IM) for Newly Diagnosed Chronic Myeloid Leukemia (CML): Initial Results from the BFORE Trial (2017) (0)
MAPK-Activation in CD34+ CML Stem Cells Induced by Selective Abl-Inhibitors Is Not Observed Using the Combined Src/Abl-Inhibitor Dasatinib. (2007) (0)
Therapie von Hirnmetastasen und Meningeosis neoplastica (2011) (0)
Efficacy and Safety of First-Line Bosutinib versus Imatinib in the BFORE trial : 18-Month Follow-up (2018) (0)
Durable Molecular Remissions in Patients with Relapsed CML Post Allogeneic Stem Cell Transplantation upon Treatment with Imatinib-Mesylate (Glivec®, STI-571). Follow-Up Results of a Phase II Open-Label Study. (2004) (0)
Recurrent fusion of PCM1 to JAK2 in atypical chronic myeloid leukemia and acute leukemia associated with the t(8;9)(p21-22;p23-24) (2004) (0)
Reviewers for Cellular Oncology in 2008 (2009) (0)
Glutathione-Depletion Potently Enhances the Cytotoxic Activity of Arsenic Trioxide in Imatinib Sensitive and Resistant Bcr-Abl Positive Cell Lines. (2004) (0)
Circulating epithelial tumor cells (CETC) during preoperative chemotherapy (CTX) of patients with gastric cancer. (2012) (0)
Campylobacter jejuni ssp. jejuni bacteraemia in a patient with BCR-ABL-positive chronic myelogenous leukaemia in remission on dasatinib therapy (2015) (0)
Hemophagocytic Lymphohistiocytosis (HLH) in adults: Results of the German HLH registry (2015) (0)
Cytoreductive Treatment in 'Real Life' - Interim-Analysis of 434 Polycythemia Vera Patients in Germany (2019) (0)
Combination of treosulfan, fludarabine and cytarabine as conditioning in patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms (2021) (0)
chronic myeloid leukemia: 2013 European LeukemiaNet recommendations for the management of (2013) (0)
PB1904: TRIAL IN PROGRESS: A PHASE III STUDY OF ASCIMINIB VS AN INVESTIGATOR-SELECTED TKI IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) (2022) (0)
Staphylococcus intermedius infection with splenic abscesses in a patient with acute lymphoblastic leukemia. (2023) (0)
Simultaneous Monitoring of Minimal Residual Disease by RT-PCR of PML/RARα and RARα/PML Fusion Transcripts in Acute Promyelocytic Leukemia (APL) (2003) (0)
Vorwort (2013) (0)
Heterogeneous prognostic impact of 9q+ deletions in patients with chronic myelogenous leukemia (2006) (0)
PF398 KNOCKDOWN OF LASP1 IN CXCR4 EXPRESSING CML CELLS PROMOTES CELL PERSISTENCE, PROLIFERATION AND TKI RESISTANCE (2019) (0)
Influenza virus infections in patients with malignancies: Characteristics and outcome of the spring season 2015-final analysis by the infectious diseases working party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) (2016) (0)
[Chronic myeloid leukemia. Current strategies in diagnosis, therapy and follow-up]. (1996) (0)
Outcome of CML patients with ABL tyrosine kinase mutations after hematological resistance to imatinib. (2004) (0)
ENDOBRONCHIAL ULTRASOUND (EBUS) FOR DETECTION OF EARLY LUNG CANCER (2016) (0)
Pan-Stakeholder Core Outcome Set (COS) Definition for Hematological Malignancies within the Framework of Harmony and Harmony PLUS Projects (2022) (0)
Identification of the Energy Stress Sensor AMPK As Therapeutic Target in Acute Lymphoblastic Leukemia (2016) (0)
Treatment Outcome with Imatinib-Based Maintenance Therapy in Elderly Patients with Philadelphia-Positive Acute Lymphoblastic Leukaemia (Ph+ALL) Ineligible for Allogeneic Stem Cell Transplantation (SCT). (2007) (0)
Kinetics of BCR-ABL Mutant Clones Determines Resistance in CML on Second Generation TKI Treatment. (2008) (0)
Favorable Outcome of Chronic Myeloid Leukemia Patients Treated with Imatinib Vs Early Allogeneic Stem Cell Transplantation. (2008) (0)
PEG-Interferon for Chronic Phase CML - Still an Option in the Era of Imatinib?. (2004) (0)
Molekulare Onkologie (2022) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Andreas Hochhaus?

Andreas Hochhaus is affiliated with the following schools:

Medical University of Vienna
Ludwig Maximilian University of Munich
University of Basel
University of Turin
University of Jena
Catholic University of Korea
Imperial College London
Kobe University
Royal Postgraduate Medical School
University of Adelaide
University of São Paulo
University of Bologna
University of Southampton
Heidelberg University

Andreas Hochhaus's Academic­Influence.com Rankings

Why Is Andreas Hochhaus Influential?

Andreas Hochhaus's Published Works

Published Works

What Schools Are Affiliated With Andreas Hochhaus?

Andreas Hochhaus's AcademicInfluence.com Rankings